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ABSTRACT 
Liesl Kerlyn Jeffers 
Salivary Gland Disease: A Role for BK Virus 
(Upon the direction of Jennifer Webster-Cyriaque) 
 
 Salivary gland disorders (SGD) cause significant morbidity but remain an enigma. 
SGD includes autoimmune disorder Sjogren’s syndrome (SS), and a related HIV-
associated salivary gland disease (HIV-SGD), that is AIDS defining in children and 
increasing in the adult population. Each of these maladies is characterized by loss of 
exocrine function resulting from chronic immune attack directed against the salivary 
glands with CD4+ (SS) or CD8+ (HIV-SGD) lymphocytic infiltrates within the gland 
tissue. The affected individuals are disfigured by facial asymmetry and 1-10% develop 
malignant lymphoproliferative disease. Further, the associated xerostomia instigates 
caries, mucosal pathology and periodontal disease. Despite progress made toward 
understanding aspects of SS, critical gaps remain in understanding the pathogenesis of 
SGD. The long term goal of this project is to make critical strides toward understanding 
the etiology of SGD in order to go beyond the ineffective palliative treatment that is 
currently the standard of care. 
 The central hypothesis of this work is that viral pathogenesis is essential to the 
development of salivary gland disease. Results show for the first time that polyomavirus, 
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BKV is associated with salivary gland disorders. BKV DNA and its gene products were 
consistently detected in HIV-SGD salivary gland biopsies and in a subset of SS patient. 
BKV was also detected in the peripheral blood and shed in oral fluids from HIV-SGD 
patients and not in control subjects. To confirm the in vivo findings an in vitro model was 
created whereby parotid and submandibular salivary gland cells were productively 
infected with BKV demonstrating each part of the viral life cycle.  Salivary gland tropism 
was confirmed and the BKV receptor on salivary gland cells was defined. BKV 
transmission and pathogenesis is not well understood. Importantly, these studies suggest 
that BKV transmission may occur via the oral route.  
Differential gene expression studies were also performed on HIV-SGD salivary 
gland biopsies.  Among the many modulated transcripts was a novel non-coding RNA, 
MALAT-1, that was highly up-regulated in the disease.   Further investigation of this 
transcript revealed that BKV infection played an important role in its regulation and we 
report for the first time a mechanism for MALAT-1 regulation.   
  
 iv
 
 
 
This work is dedicated to the people in my life who always reminded me that I 
could do anything, no matter what:  in no particular order, Jean Jeffers, Cecil Jeffers, 
Jeina LookLoy, Lynnette Ransome, Vincent Ransome, Lavaughn Jeffers, Marlon Jeffers, 
Ray Jeffers, Camille Bruce, Yvonne Ransome, Dwayne Francis, Jennifer Webster-
Cyriaque, Len Jeffers, Ken Jeffers, Ron Jeffers, Keith Ransome, Brian Jeffers, Roger 
Ransome, Yvette Ransome, Latoya Gay, Linton Ransome, Aunt Shirley, Ian Jeffers, 
Aunt Val, Aunt Urla, Laka Ford-Williams, Carleen Thomas-O’Connor, Dillon, Kerwin 
and Reah Bartholomew,  and all my family and friends.    
 v
 
 
 
 
 
ACKNOWLEDGEMENT 
 
 
I would like to thank my advisor, Dr. Jennifer Webster-Cyriaque for all her help 
and guidance on this project. Without her expertise in the field of oral pathogens, this 
project would have been very difficult. I would additionally like to thank her for allowing 
me to join her lab during my third year of graduate school. I am eternally grateful that she 
was able to see my potential and take me under her wings. Her support and 
encouragement has allowed me to grow and develop into a successful scientist and 
individual.  
I would also like to thank the members of Webster-Cyriaque lab, for their support 
and creating a welcoming lab environment. Special thanks to lab member Dr. William 
Seaman for sharing his wealth of knowledge and expertise with me. I am also grateful to 
Dr. Sharon Milgram for her guidance during my years of graduate school as well as to 
my graduate school roommate of five years, Dr. Michelle Smith.  
Special thanks to Dr. Bruce Baum, Dr. Robert Bagnell, Donna Thompson, Debbie 
Granger, Dr. Allen Dovigi and Victoria Madden. I would also like to thank the members 
of my committee: Dr. Ronald Swanstrom, Dr. Glenn Matsushima, Dr. Nancy Raab-Traub 
and Dr. Volker Nickeleit for all of their helpful advice in the development of the work 
presented in this dissertation.  
Finally, I would like to thank Dr. Kaiwen Duan who started this BKV project and 
paved the way for my dissertation. 
 vi
 
 
 
TABLE OF CONTENTS 
 
LIST OF TABLES…………………………………………………….......…..........…....ix  
LIST OF FIGURES………………………………………………..……...……....….…..x 
ABBREVIATIONS……………………………………………………….…...…......…xii 
CHAPTER 1: INTRODUCTION 
 Salivary Gland Diseases………………………………………….….......…....…..2 
  HIV-associated Salivary Gland Disease (HIV-SGD)…….…......………..2 
Diffuse infiltrative lymphocytic syndrome (DILS)………….............…....5  
Sjogren’s Syndrome…………………………………………............…....6 
SGD’s: infectious etiologic agents? .......................................................................9 
Viruses and salivary gland disorders……………………………...……...….…..10 
Differentially expressed genes in salivary gland disorders…………...........……14 
Polyomaviruses…………………………..…………………...…….............…....15 
BKV………………………………………………………..…...……......……...19 
Virion Structure….……….……………........……...……….….…..…....19 
Genome Organization…………………………………...……....….……19 
Life Cycle……………………………………………...…….....………..23 
 vii
Route of transmission and seroconversion…….…………...……………24   
Pathogenesis, dissemination and persistence………...……………….….25 
BKV-associated diseases……………………………………………….……………......26  
BKV in Immune suppression...…………………………………..…………..…..26 
BKV-associated nephropathy (BKN)...…………………..….……..……26 
Hemorrhagic cystitis………………...……………………...…....…..…..27 
Human Immunodeficiency Virus……………….……….………......…...28 
Autoimmune disease…………………….……………….…………..…..29 
BKV and Cancer……………………………………………….………………...30 
Objectives……………………………………........…………………….…...............…..31 
References………………………………………………………………………………..34 
 
CHAPTER 2: HIV-SALIVARY GLAND DISEASE IS ASSOCIATED 
WITH BK VIRUS 
 Abstract……………………………………………………....…………………..49  
 Introduction………………………….………………………..…….……………50 
 Materials and Methods…………………………………………………………...52 
 Results…………………………………………………………....………………55 
Discussion………………………………………………………....……………..65 
 References……………………………………………………….……....……….69 
CHAPTER 3: BK VIRUS DETECTED IN SALIVARY GLANDS OF  
SJOGREN SYNDROME 
Abstract…………………………………………………….………....……..…...73 
 Introduction………………………………………………….……....…..……….74 
 Materials and Methods…………………….………………….……....…….……75 
 viii 
 Results…………………………………….…………………………...…………78 
Discussion………………..………………….…………………………...………84
 References………………………………….……………………………...……..87 
CHAPTER 4: BK VIRUS UP-REGULATES A NOVEL NON-CODING 
RNA ASSOCIATED WITH METASTASIS, MALAT-1 
Abstract…………………………………….……………………………...……..90 
 Introduction…………………………………….………………….……..………91 
 Materials and Methods…………...…………….………………….…..………...94 
 Results…………..……………………………….………………..….…...……100 
Discussion……………………...………………….…………….……..………110 
 References……………………...……………….………………………...……115 
CHAPTER 5: BK VIRUS HAS TROPISM FOR HUMAN SALIVARY 
GLAND CELLS IN-VITRO: IMPLICATIONS FOR TRANSMISSION 
Abstract...………………………………………………….…………...……….118 
 Introduction……………………………………………………………………..119 
 Materials and Methods……………………….……………………….…..…….121 
 Results…………………………………………………………………………..127 
Discussion……………………………………....………….……….…..…...…144
 References…………………………………………………….…………...……148 
CHAPTER6: GENERAL CONCLUSION 
 References……………………………………………………….……………...161 
 
 
 
 
 ix
LIST OF TABLES 
 
 
CHAPTER 1 
Table 1.1 Comparison of salivary gland disorders: HIV-associated  
Salivary Gland Disease vs. Sjogren’s Syndrome………………………..….……………..8 
Table 1.2 Viruses detected in the salivary gland....………………………..…..………...13 
Table 1.3 The Polyomaviruses………………………………………..………….….…...17 
 
CHAPTER 4 
Table 4. Genes up-regulated in HIV-SGD using suppressive  
subtractive hybridization…………………………………………………..………..…....93 
 
 
 
 x
LIST OF FIGURES 
CHAPTER 1 
Figure 1.1 Virion structure and genomic organization of BK virus…................……......21 
CHAPTER 2 
Figure 2.1. Detection of Polyomavirus DNA in HIV-SGD and 
not Herpesviral DNA in HIV SGD………………………………….….…………..……56 
Figure 2.2.  Detection of BK virus in HIV-SGD….………..........…....….……….......…59 
Figure 2.3.  Detection of BKV gene expression in HIV-SGD………...…..….…..……...62   
Figure 2.4. Detection of BKV viremia and shedding in oral fluids 
of HIV-SGD………………………………………………………….………...………...64   
 
Figure 2.5.  Proposed Role for BKV as an infectious agent in the  
development of HIV-SGD………………………………………..….……………..……68 
CHAPTER 3 
Figure 3.1. BKV DNA detected in a subset of SS patients…………………......….……79  
Figure 3.2. Sequence analysis confirmed the detection of BKV  
DNA in SS……………………………........……………………………......….....…..…80 
Figure 3.3. BKV gene expression in a subset of SS……………………....…..…..……..82 
Figure 3.4. Up-regulation of a novel non-coding RNA, MALAT-1  
in a subset of SS…………………………………………………………….………..….84  
CHAPTER 4 
Figure 4.1. Up-regulation of MALAT-1 in salivary gland disease…….……...…..……103 
Figure 4.2. BKV detected in salivary gland biopsies of HIV-SGD 
patients…………………………………………………………….………………....…105 
Figure 4.3. BKV up-regulates MALAT-1 transcript in vitro…………….…………......108 
Figure 4.4. BKV infection up-regulates MALAT-1 promoter activity……....…...........111 
 
 xi
CHAPTER 5 
Figure 5.1. BKV DNA detection in oral fluids……………………………...…….……128 
Figure 5.2. Detection of BK virions in salivary gland cell lines infected 
with BKV………………..…………………………………………………….…...…...130 
Figure 5.3. BKV replicates in human salivary gland cells..............................................132 
Figure 5.4. BKV protein expressed in salivary gland cells………………..……..……..134 
Figure 5.5. BK virions detected within salivary gland cells………………....…………135 
Figure 5.6. Encapsidated BK virions released from human salivary  
gland cells…………………………………………………………………........…....…137 
Figure 5.7. Infectious virus released from HSG cells ..……….…………..........………139 
Figure 5.8. Inhibition of BKV infection in salivary gland cell lines  
via gangliosides………………………………………………………….…….…..……142   
CHAPTER 6 
Figure 6. Proposed model of BKV pathogenesis in a patient with salivary gland  
disease………...……………………………………………………………...………....160  
 
 
 
 xii
ABBREVIATIONS 
 
 
AIDS   Acquired immunodeficiency syndrome 
ANA   Antinuclear antibodies 
APV   Avian polyomavirus 
ART   Antiretroviral treatment 
BFDV   Budgerigar fledgling disease virus 
BKN   BK nephropathy 
BLC   Benign Lymphoepithelial Cysts 
BMT   Bone marrow transplant 
bp   Base pair 
BSA   Bovine serum albumin 
ByPV   Bovine polyomavirus 
C   Catalytic 
cDNA   complementary DNA 
CMV   Cytomegalovirus 
CsC1   Cesium chloride 
CSF   Cerebral spinal fluid 
DILS   Diffuse infiltrative lymphocytic syndrome 
DMEM  Dulbecco's minimal essential medium 
DNA   Deoxyribonucleic acid 
EBV   Epstein-Barr virus 
EMC   Encephalomyocarditis 
EMSA   Electrophoretic mobility shift assay 
 xiii 
ER   Endoplasmic reticulum 
FBS   Fetal bovine serum 
Go   Growth zero 
h   Hour 
HAART  Highly active antiretroviral therapy 
HaPV   Hamster papovavirus 
HC   Hemorrhagic cystitis 
HHV   Human herpervirus 
HHV-6  Human herpes virus 6 
HHV-7  Human herpes virus 7 
HIV   Human Immunodeficiency virus 
HLP   Hairy leukoplakia 
HPTE   Human proximal tubule epithelial 
HPV   Human papillomavirus 
HSG   Submandibular salivary gland cells 
HSY   Parotid gland salivary gland cells 
HTLV   Human T lymphotropic virus 
IFITM1  IFN- induced transmembrane proteins 
IHC   Immunohistochemical 
IRD   Immune reconstitution disease 
ISGF3G  Interferon- stimulated transcription factor 3y 
JCV   JC virus 
kb   Kilobase 
 xiv
kD   kilodalton 
KPV   K Papovavirus 
KPV   Kilham Virus 
KS   Kaposi's sarcoma 
KS   Kaposi's sarcoma 
KSHV   Kaposi's sarcoma herpes virus 
LPV   Lymphotropic papovavirus 
LT Ag   Large T antigen 
MALAT -1  metastasis- associated lung adenocarcinoma transcript-1 
MCC   Merkel cell carcinoma 
MCMV  Mouse cytomegalovirus 
MCV   Merkel cell polyomavirus 
MHC   Major histocompatibility complex 
MMTV -LTR  Mouse mammary tumor virus long terminal repeat 
mRNA   Messenger RNA 
MSG   Minor salivary glands 
MT Ag  Middle T antigen 
NCCR   Noncoding control region 
OC   Oral candidiasis 
PBMC   Peripheral blood mononuclear cells 
PBS   Phosphate buffer solution 
PCR   Polymeraase chain reaction  
pi    Post infection 
 xv
PIV   Parainfluenza virus 
PP2A   Structural subunits of protein phosphatase 
pSS   Primary Sjogren's syndrome 
PyV -MT  Polyomavirus middle T 
RKV   Rabbit kidney vacuolating virus 
RNA   Ribonucleic acid 
RPV   Rat polyomavirus 
RT-PCR  reverse transcriptase PCR 
SGD   Salivary Gland Diseases 
SLE   Systemic Lupus Erythematosus 
SS   Sjogren's syndrome 
SSH   Suppression subtractive hybridization 
sSS   Secondary Sjogren's syndrome 
ST Ag   Small T antigen 
STMV   Stump- tailed macaque virus 
TAR   Transactivation response 
TLR   Toll- like receptor 
tRNA   Transfer RNA 
vDNA   viral DNA 
VP   Viral protein 
  
 
CHAPTER 1 
 
INTRODUCTION 
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Salivary Gland Diseases 
Salivary gland disorders cause significant morbidity in both immune competent 
and immune suppressed populations.  While some of these diseases have been well 
characterized, the etiology of others remains an enigma.  Salivary gland diseases are 
generally characterized by pain or swelling of saliva-producing tissues in the mouth. 
Saliva-producing tissues include three major salivary glands, the parotid, sublingual and 
submandibular glands. Saliva from the major salivary glands enter the mouth through 
ducts at various locations in the mouth. Additionally there are numerous minor salivary 
glands distributed throughout the oral cavity.  
Two major manifestations of salivary gland disorders include reduced saliva 
production and salivary gland swelling. Dry mouth or xerostomia occurs when saliva 
production is insufficient or almost nonexistent. Xerostomia predisposes the individual to 
oral candidiasis, rampant tooth decay, and progressive periodontal disease [1]. Salivary 
gland swelling can be caused by blockage of one of the ducts that transport saliva.A 
sialolith or stone is the most common cause of blockage,  however infectious diseases 
such as hepatitis and AIDS and autoimmune diseases including Sjögren's syndrome, 
diabetes mellitus, and sarcoidosis may be accompanied by swelling of the major salivary 
glands. Salivary gland enlargement can also result from cancerous or noncancerous 
tumors in the salivary glands. 
 
HIV-associated Salivary Gland Disease (HIV-SGD) 
HIV-SGD is AIDS defining in pediatric HIV infection and is increasing in the adult 
HIV population. The term HIV-SGD was first coined by Schiodt et al [2] to describe an 
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enlargement of major salivary glands and/or by complaint of xerostomia in the absence of 
xerogenic agents, medications, and diseases known to cause xerostomia in HIV patients 
[3]. In HIV-SGD, quantitative changes occur in the saliva, such as lower secretory rates 
of sodium, calcium chloride, cystatin, lysozyme and total anti-oxidant capacity which 
alters the homeostasis of the oral cavity and results in significant morbidity during the 
progression of HIV disease [4]. Typically, HIV-SGD presents as a unilateral or bilateral 
diffuse soft swelling resulting in facial disfigurement, and may be associated with pain. 
Histologically, HIV-SGD is characterized by hyperplastic intraparotid lymphnodes 
and/or lymphatic infiltrates within the salivary gland tissue. This lymphocytic infiltrate 
consists predominantly of CD8 T cells which are also CD29+, indicative of a memory 
cell phenotype. Recent histochemical analysis has revealed the location of the infiltrate as 
periductal with acinar atrophy, ductal dilation and mild to moderate fibrosis with collagen 
deposition [5-6].  The minor salivary glands are also affected in HIV-SGD with labial 
salivary glands demonstrating features of sialdenitis. 
HIV-SGD has been universally established as among the most important AIDS-
associated oral lesions.  Oral lesions are important clinical indicators of HIV/AIDS by 
suggesting HIV infection in the undiagnosed individual, indicating clinical disease 
progression and predicting development of AIDS [7]. CD4 cell counts and high HIV viral 
load have been strongly associated with specific common oral lesions suggesting that oral 
disease manifestation may serve as a potential clinical marker for HIV viremia and 
disease progression. Since the introduction of highly active antiretroviral therapy 
(HAART) in the mid-1990s, the prevalence of types of oral cavity infections of HIV-
infected patients has changed across time, with hairy leukoplakia (HLP), oral candidiasis 
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(OC) and oral Kaposi’s sarcoma (KS) decreasing and the incidence of HIV-SGD 
increasing [8-9]. For example, in an HIV-infected North Carolina population, HIV-SGD 
has gone from 1.8% in an early cohort to 5.0% in a late cohort [9]. This increase in HIV-
SGD after the introduction of HAART drug regimen is reminiscent of previously 
described cases of immune reconstitution disease (IRD). In HIV infected patients, IRD is 
an adverse effect of a restored immune response during initial treatment with HAART 
[10]. Rizos et al described a patient on HAART with excellent immunological and 
virological response and parotid gland enlargement that may have reflected immune 
reconstitution [11]. IRD typically occurs as a result of a pre-existing opportunistic 
infection or a subclinical infection becoming "unmasked" upon the introduction of 
HAART treatment when HIV viral load decreases and CD4 count increases. Therefore, 
HIV-SGD presenting as an IRD implies that an infectious agent may play a role in its 
etiology. 
In a prospective study by Mastroianni [12], the association of another salivary gland 
disease, Sjogren’s Syndrome (SS) with the progression of HIV-related disease in a cohort 
of HIV patients treated with HAART was evaluated.  In this study, out of the 150 HIV-
positive patients treated with HAART, four were positive for SS whereas none of the 
HIV positive patients not treated with HAART fulfilled the diagnostic criteria for SS. In 
conclusion, the study suggested that HAART treatment may play an important role in the 
aetiology of SS, and that SS may be a new and important complication of long-term 
HAART regimens[12].  Interestingly, the majority (¾) of these patients did not express 
the autoantibodies typical of SS and thus probably had HIV-SGD.  This study highlights 
the clinically identical nature of the two diseases and provides further evidence that HIV-
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SGD increases with HAART therapy.  As more people receive HAART therapy the 
potential for increasing incidence of HIV-SGD grows. 
In developing countries the incidence of HIV-SGD has been reported to be as high as 
48% of HIV-1 infected patients [13]. Parotid gland lesions are generally much larger and 
more disfiguring in pediatric patients than in adults, and in most children xerostomia is 
not usually associated with the parotid swelling, although in adult patients it is a fairly 
common complaint. In both adults and children the lesion often occurs in conjunction 
with generalized lymphadenopathy. Reasons for the differences between the adult and 
pediatric manifestations are not yet understood [14]. In children with HIV infection it has 
been shown that the presence of salivary gland enlargement is associated with less rapid 
progression to death than is found in those with OC or herpes simplex.  The time to death 
averages 5.4 years, compared with 3.4 years with OC [15]. This may be due to a 
protective effect of the CD8 T cells that predominate in the lymphocytic infiltrate in the 
salivary glands in that condition and are part of diffuse infiltrative lymphocytic syndrome 
(DILS) [8, 16-17]. The HIV-SGD disease process is of particular interest because in 1-
2% of patients, malignant lymphomas have been described in association with these 
glandular lesions making this disease a premalignant lesion [18-19].  
 
Diffuse infiltrative lymphocytic syndrome (DILS)  
HIV-SGD reflects a localized manifestation of DILS that occurs in the parotid gland 
of HIV- positive persons. DILS was first described by Itescu et al [20] and is 
characterized by salivary and lacrimal glandular swelling and sicca symptoms of varying 
intensity accompanied by persistent circulating and visceral CD8+ lymphocytic 
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infiltration of parotid and lacrimal glands, lungs, kidneys, nerves, muscles, and lymph 
nodes, in association with HIV infection. DILS has also been designated as a cystic 
lymphoid hyperplasia of AIDS and is a close phenotypic mimic of Sjogren’s Syndrome 
in terms of sicca symptoms, salivary glandular enlargement, histology and predisposition 
to develop non-Hodgkin’s lymphoma. The difference between DILS and Sjogren’s 
syndrome, however lies in the frequent occurrence of extraglandular sites of lymphocytic 
infiltration in DILS, the nature of the infiltrating lymphocytes, that is, CD8 in DILS 
versus CD4 in Sjogren’s syndrome, and the scarcity of serum autoantibodies in DILS 
[17]. Several conditions that look similar to DILS and can be misdiagnosed include 
salivary gland tumors, parotitis, tuberculosis, sarcoidosis and sialadenosis. [21]. Similar 
to HIV-SGD, patients with DILS appear to be at a significantly increased risk of 
malignant lymphomas [22].  
 
Sjogren’s Syndrome 
Both HIV-SGD and DILS present Sjogren’s syndrome-like conditions in the oral 
cavity. Table 1.1 shows a comparison of salivary gland disorders: Sjogren’s syndrome 
and HIV-SGD. Sjogren’s syndrome (SS) is an autoimmune inflammatory disorder 
characterized by an infiltration of CD4 lymphocytes in the exocrine glands, especially the 
lacrimal and salivary glands with extraglandular manifestations in approximately 30 
percent of cases. SS prevalence in the general population is largely unknown however 
women are affected nine times more frequently than men. Although SS was first 
described in the late 1800’s its etiology is currently unknown. Genetic, infectious, 
endocrine and psychoneuroimmunological factors have however been postulated to play 
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a role in disease manifestation.   SS is typically diagnosed either as primary SS (pSS) or 
secondary SS (sSS). Both classifications of SS manifest as a systemic disease with 
several organs affected including, kidneys, lung, blood vessels, skin and muscles and 5-
10% of patients develop malignant lymphoproliferative disease. However, in sSS in 
addition to the above described manifestations various autoimmune diseases such as 
rheumatoid arthritis, systemic sclerosis, systemic lupus erythmatosus and myositis also 
occur. SS patients typically are also positive to Ro and La autoantibodies. Patients with 
autoantibodies have an increased risk to develop parotid swelling, respiratory symptoms, 
lymphadenopathy and lymphoma. Whereas anutoantibody negative patients though 
unlikely to develop significant systemic features are still at risk of developing connective 
tissue diseases distinct from SS. [12]. 
 
 
 
 
 
 
 
 
 
 
 
 8
Table 1.1. Comparison of salivary gland disorders:  
HIV-associated Salivary Gland Disease vs. Sjogren’s Syndrome 
 
HIV-SGD/DILS SS 
• an AIDS defining illness in pediatric 
HIV infection, affecting up to 60% 
of children worldwide 
• incidence is increasing in the adult 
HIV population and post HAART 
has become a hallmark of HIV- 
associated immune reconstitution 
syndrome 
• Infiltration of CD4+ T cells  
 
• the second most common 
autoimmune rheumatic disease, 
affecting ~1 – 2 million Americans, 
affects women 9x more frequently 
than men  
• EBV, KSHV, Coxsackie and HTLV 
have been investigated as potential 
etiologic agents 
• Infiltration of CD8+ T cells 
 
 9
 SGD’s: infectious etiologic agents? 
 In HIV-SGD, epidemiologic data point to an antigen driven process. Basu et al 
[23] described a prospective study in which he observed that the epidemiology, clinical 
presentation and certain extraglandular manifestations of HIV-SGD/DILS have changed, 
concomitant with the introduction of HAART, suggesting that DILS is an antigen (viral)-
driven response and the primary treatment for it is anti-HIV therapy[23]. Further 
evidence alluding to an infectious etiologic agent is the data showing different rates of 
HIV-SGD in children (20-47%) versus adults (3-7.8%) [19]. In Chapter 2 of this thesis, 
we postulate that this may indicate primary viral infection in children versus residual 
immunity in adults. Further, the infiltrating lymphoid cells present during HIV-SGD 
point to an antigen driven MHC-determined host immune response [17]. That the 
lymphocytosis within HIV-SGD is phenotypicaly an antigenically driven response may 
also implicate an infectious agent present during HIV immunosuppression. 
 It has been postulated that SS autoimmune disease is primed by viral infection. 
There is evidence that the type 1 interferon pathway is highly stimulated locally and 
systemically in SS [24]. Also it has been suggested that viruses may initially infect the 
gland leading to production of type 1 interferon by plasma dendritic cells. Interferon 
would then activate the adaptive immune system. Activation of the adaptive immune 
response would then result in auto-antibody immune response even in the absence of 
virus.   In the following section we explore previously published associations of viral 
infection and SS. 
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Viruses and salivary gland disorders 
There is a long association between viral infections and diseases of the salivary 
gland.  In general, viral infections of the salivary gland may result in reduced saliva 
production and/or swelling. Mumps is the most common salivary gland infection caused 
by paramyxovirus. Paramyxovirus is transmitted by droplet infections carried in the 
saliva. There is a primary viral infection of the oral cavity and a multiplication of the 
virus in the upper respiratory tract and the regional lymphnodes. Paramyxoviral infection 
causes bilateral swelling of the parotids, although the other salivary glands may also be 
affected. However, subsequent to vaccine development the incidence of mumps has 
drastically been reduced.  
Several viruses, including DNA, RNA and retroviruses have been considered 
important co-factors in the development of SS [12]. The two DNA viruses that have been 
studied in association with pSS are cytomegalovirus (CMV) and Epstein–Barr virus 
(EBV)[25-31]. Overall, the data regarding CMV and EBV as causative agents for SS are 
contradictory and, because pSS does not occur in most cases of viral reactivation in vivo, 
the link between reactivation and autoimmunity induction remains to be established. Two 
RNA viruses have been detected within the salivary gland of SS patients: Hepatitis C and 
coxsakievirus, both of which require more investigation before they are classified as 
being the etiologic agent of SS [32-33]. Interestingly, four different retroviruses have 
been associated with pSS: human T lymphotropic virus type 1 (HTLV-1), human 
immunodeficiency virus (HIV), intracisternal A type particles and human retrovirus 5 
[34-37]. However, only HTLV-1 and HIV produce a Sjogren’s-like syndrome with 
significant pathologic and clinical differences from pSS. 
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In HIV positive patients, Rivera et al. identified HIV p24 protein expressed in the 
salivary glands by immunohistochemistry technique [6]. Rivera’s group was also able to 
identify Epstein-Barr virus (EBV) protein but not cytomegalovirus (CMV) by 
immunohistochemistry in the salivary glands of HIV patients [6]. Human herpesvirus  6 
(HHV-6) and HHV-7 were also demonstrated in salivary glands and in saliva in HIV 
positive persons [38] however their presence has not been attributed to etiological 
importance for salivary gland lesions. The lymphocytic infiltration observed in HIV-
SGD/DILS may be an antigen driven event due to the presence of infection of the 
salivary gland. Other studies have also looked at the role of CMV, EBV and Kaposi’s 
sarcoma herpes virus (KSHV) in Benign Lymphoepithelial Cysts (BLC) of the parotid 
gland. Yen et. al however, concluded that CMV and KSHV were not associated with 
BLCs, although EBV was found  more frequently in BLC than in normal parotid controls 
[39]. Table 1.2 lists viruses that have been detected within the salivary gland and their 
disease association. 
Multiple viruses are also associated with SGD development in animals. The ability of 
sialotropic murine CMV (MCMV) to induce acute and chronic salivary glandular disease 
in an autoimmune-prone mouse strain was recently described [40]. Encephalomyocarditis 
(EMC) virus-induces sialodacryoadenitis in mice [41]. Papovaviruses have also long 
been associated with salivary gland disease development in experimental animals. 
Murine infection with polyomaviruses is associated with parotid gland tumorigenesis and 
has been implicated in human carcinogenesis [42]. Athymc nude mice were found to 
develop a wasting disease accompanied by parotid sialoadenitis with intranuclear 
inclusion bodies in acinar and ductal epithelial cells. Intranuclear inclusions and 
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cytoplasm of the parotid epithelium were found to express SV40 antigens [43]. Salivary 
epitheliomas induced by injection of neonatal mice with mouse polyoma virus were 
infiltrated with immature T lymphocytes[44]. This infiltration is reminiscent of SGD. 
These infiltrates were also described in tumors that arose at the site of inoculation in 
newborn guinea pigs inoculated with SE polyomavirus [45]. A transgenic mouse model 
in which the Polyomavirus middle T (PyV-mT) oncogene is expressed under the control 
of the mouse mammary tumor virus long terminal repeat (MMTV-LTR) has been 
described which displays clinically observed salivary gland enlargement similar to HIV-
SGD [46]. PyV-mT produces a tumorigenic phenotype when expressed alone in cell lines 
and animals making it a very useful tool for studying oncogenic signaling pathways  [47]. 
As suggested by the body of work reviewed above viral infection is tightly 
associated with salivary gland pathology (Table 1.2).   With the exception of mumps 
virus and PIV, the majority of these human studies only detect viral nucleic acid but do 
not determine whether salivary gland tissues are actually permissive for these agents.   
The potential for a viral etiologic agent in HIV-SGD and potentially SS are highly 
feasible.  This possibility is explored in Chapters 2 and 3 of this dissertation.  
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Table 1.2 Viruses detected in the salivary gland 
Virus  Associated disease(s) 
Paramyxovirus Mumps[48]  
Human Immunodeficiency virus (HIV) HIV-SGD[49], SS[35] 
Epstein Barr virus (EBV)  BLC[39], Salivary gland tumors[50], 
SS[26] 
Cytomegalovirus (CMV)  Sialdentitis[51] 
Coxsakievirus SS [33] 
Human T-lymphotropic virus (HTLV)  SS[35, 37, 52] 
Human herpes virus 6 (HHV-6)  Parotitis [38, 53]} 
Human herpes virus 7 (HHV-7)  Parotitis[38, 54] 
Kaposi sarcoma virus (KSHV)  Warthin’s tumor[55] SS associated 
parotid MALT lymphomas[56] 
Influenza  Parotitis[57] 
Parainfluenza virus (PIV)  Parotitis[58] 
Guinea Pig CMV Guinea pig CMV infection[59], 
Hepatitis C SS reviewed in[32] 
Mouse CMV (MCMV) Acute and chronic SGD[40] 
Mouse polyomavirus (PyV) Mouse parotid tumor[60] 
Encephalomyocarditis (EMC) Sialodacryoadenitis 
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Differentially expressed genes in salivary gland disorders 
 An understanding of the gene expression profile specific to salivary gland 
disorders is likely to provide a framework for a more selective investigation of the 
molecular mechanisms of the disease, to identify an etiologic agent and for the 
identification of therapeutic targets. Several studies investigating differential gene 
expression in salivary gland disorders, specifically SS, have been performed including 
the use of mouse models and human biopsies. In studies performed by Hjelmervik et. 
al[61] and Gottenberg et. al [62] using microarray analysis, they observed over-
expression of many immune response genes  in SS, including interferon inducible genes 
for example interferon-stimulated transcription factor 3γ (ISGF3G) and IFN-induced 
transmembrane proteins (IFITM1). These genes were induced by either IFN-α or IFN-γ 
in vitro in salivary gland epithelial cell cultures. The latter group also found significantly 
increased expression of toll-like receptor (TLR) 9 and TLR8 in salivary gland biopsies 
from SS patients [62]. TLR8 and TLR9 sense nucleic acids (single-stranded RNA and 
prokaryotic unmethylated CpG-DNA, respectively) on endosomal membranes. The 
identity of the interferon-inducing nucleic acids in the SS salivary glands remains elusive 
but suggests the potential for the presence of an infectious agent. 
Unpublished data from our lab have also identified deregulation of several genes 
in biopsied salivary glands from HIV-SGD patients compared to healthy controls using 
micro array analysis and subtractive suppressive hybridization (SSH) techniques. Some 
of the genes modulated were consistent with the activation of type 1 interferon response 
elements including MHCII, interferon inducible genes including cytochrome P450 and 
IFITM1 which are consistent with an antigen driven immune response.  
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In addition, 25% of the modulated genes detected by SSH had unknown function. 
The unknown gene with the most number of clones detected was a novel non-coding 
RNA called metastasis-associated lung adenocarcinoma transcript 1, MALAT-1. The 
MALAT-1 gene, also known as α gene, is found on chromosome 11q13 and is well 
conserved among the mammalian species [63]. The MALAT-1 transcript has been shown 
to localize to the nucleus [64] and currently has no known function except that its 3’ end 
can be processed to yield a tRNA-like cytoplasmic RNA[65]. MALAT-1 is widely 
expressed in normal tissue and while little is known about its function, appears to be a 
potentially generic marker for epithelial carcinomas [63, 66-70]. MALAT-1 has been 
found to be up-regulated in lung adenocarcinoma metastasis [63], endometrial stromal 
sarcoma of the uterus [68] and non-hepatic human carcinomas [67]. MALAT-1 up-
regulation has also been shown to be a predictor of unfavorable osteosarcoma drug 
therapy outcomes [66].   Chapter 4 of this dissertation investigates the potential function 
of MALAT-1 in salivary gland disorders. 
 
Polyomaviruses 
As suggested by the body of work reviewed above, polyomaviral infection in animal 
models are associated with salivary gland pathology. Rise in the incidence of Polyoma 
viruria has been observed in HIV infected individuals[71], therefore it is easy to imagine 
that polyomavirus, BKV which infects approximately 80% of the population can be 
reactivated in immune compromised HIV and SS patients and infect the salivary gland 
resulting in salivary gland pathology. 
 16
Eighteen members of the Polyomaviridae family have been identified and all have 
similar size capsids constructed from three viral capsid proteins. All have genomes of 
about 5,000 base pairs and display a similar genomic organization. Many regions of their 
genomes are highly conserved, demonstrating that they have descended from a common 
ancestor. Different family members of the genus infect different species of mammals, 
including humans, other primates, rodents, rabbits, as well as birds. Most of these viruses 
however, display a narrow host range and do not productively infect other species. Table 
1.3 lists the members of the Polyomaviridae family and their natural hosts. 
The first human polyomaviruses were identified in 1971 by two independent research 
groups. Gardner et al isolated BK virus (BKV) from the  urine of a renal transplant 
patient with the initials B.K. [72], while Padgett et al  isolated JC virus from the brain of 
a Hodgkin’s lymphoma patient with the initials J.C who was also diagnosed with  
progressive multifocal leukencephalopathy [73]. Most people worldwide become infected 
with and acquire antibodies to these viruses during childhood, with no apparent disease 
manifestations. These viruses then appear to lie dormant in the cells of a subset of 
infected people, and reactivate during  
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Table 1.3 The Polyomaviruses 
 
Human WU 
Human KI 
Human Merkel cell polyomavirus (MCV) 
Rabbit Rabbit kidney vacuolating virus (RKV) 
Baboon Simian agent 12 (SA12) 
African green monkey Lymphotropic papovavirus (LPV) 
Bovine Bovine polyomavirus (ByPV) 
Bird Budgerigar fledgling disease virus (BFDV) 
Stump-tailed macaque Stump-tailed macaque virus (STMV) 
Rat Rat polyomavirus (RPV) 
Hamster Hamster papovavirus (HaPV) 
Bird Avian polyomavirus (APV) 
Mice Kilham virus (KPV) 
Mouse K papovavirus (KPV) 
Human JC virus (JCV) 
Human BK virus (BKV) 
Rhesus monkey Simian virus 40 (SV40) 
Mouse Mouse polyomavirus (MPyV) 
Host species Virus 
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immunosuppression such as in AIDS or transplant recipient patients. Recently, three 
novel human polyomaviruses have been described, KI, WU and Merkel cell 
polyomavirus (MCV). KI and WU were identified from patients with respiratory tract 
infections using large-scale high-throughput screens [74-76].  Merkel cell polyomavirus 
(MCV) was identified using digital transcriptome subtraction in Merkel cell carcinoma 
(MCC) and is thought to be the likely causative agent of MCC [77]. The Rhesus 
macaques virus SV40 was accidently introduced into the human population via 
contaminated vaccines, however antibodies against SV40 have been recently detected in 
individuals who never received the vaccine nor had contact with primates [78]. Therefore 
SV40 may be considered as a human virus [78-79].     
Mouse polyomavirus was the first member of the Polyomaviridae family to be 
discovered  and was appropriately named because it caused a variety of different types of 
tumors including salivary gland tumors.[60]. The initial impetus for studies of the 
Polyomaviridae was their oncogenic potential. Some of these viruses are capable of 
inducing tumor formation in newborn hamsters. Also, infection of cultured cells in which 
these viruses cannot grow productively often leads to the malignant transformation of 
these cells. [80]. Transforming properties of the polyomavirus are encoded by its 
oncogenic antigens, large, middle and small T antigens, each expressing complementaty 
activities. Studies to understand the oncogenic potential of these viruses have provided 
fundamental insights into cell cycle regulation, oncogenes, and tumor suppressor genes. 
Some of these viruses are easy to cultivate in tissue culture and to purify, making them 
suitable model systems for diverse studies in molecular biology.  
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The association of polyomaviruses, specifically BKV, in the development of salivary 
gland disease in experimental animals has led us in Chapter 2 and 3 to investigate their 
potential role in human salivary gland disorders. 
 
BKV 
Virion Structure 
 BKV is a non-enveloped virus with 40.5- 44 nm diameter icosahedral capsid 
(Figure 1.1A). The capsid contains three virus-encoded proteins, VP1, VP2 and VP3, 
surrounding a single molecule of viral DNA complexed with cellular histones in the form 
of chromatin. These proteins are arranged to form a T=7 icosahedral capsid containing 
360 molecules of the major capsid protein, VP1, organized into 72 pentamers. A single 
VP2 or VP3 molecule associates with each pentamer. Only VP1 molecules are exposed 
on the outside of the virion. VP1 contains a small groove that interacts with gangliosides 
GM1, GD1b and GT1b, all of which contain an α2-3-linked sialic acid residue [81-82] on 
cell surfaces. The virus particle is 88% protein and 12% DNA and has a sedimentation 
coefficient of 240S in sucrose density gradients. Because they lack envelopes, the virus 
particles are resistant to lipid solvents. They are also resistant to heat inactivation. Virions 
have a density of 1.34g/ml in cesium chloride (CsCl) equilibrium density gradients, 
whereas empty capsids have a density of 1.29 g/ml [80].  
 
Genome Organization 
The genome is a closed circular double-stranded molecule of DNA approximately 
5.3kb in length (Figure 1.1B). BKV shares a 75% sequence identity with polyomavirus 
 20
JCV and a 70% identity with SV40 [83-84]. Physical maps of the BKV genome were 
quickly generated in the 1970’s [80] with the advent of restriction endonucleases. BKV’s 
circular genome can be divided into three functional regions: (i) the early region encodes 
the regulatory proteins large tumor antigen (LTag) and small tumor antigen (STag); (ii) 
the late region encodes for the structural capsid proteins VP1, VP2, VP3 and the 
agnoprotein; and (iii) the noncoding control region (NCCR) which harbor the origin of 
replication and the sequences involved in the transcriptional regulation of both the early 
and late genes. The early region is by definition, that portion of the genome transcribed 
and expressed early after the virus enters the cell, and it continues to be expressed at late 
times after infection, after the onset of viral DNA replication.  The mRNAs encoding for 
LTag and STag are produced by alternative splicing from a common pre-mRNA. Removal 
of the LTag intron splices the first exon with the next exon allowing translation of LTag. 
Alternatively, retention of the intron allows translation to reach a termination codon within 
the intron resulting in STag. LTag is a multifunctional protein with distinct domains 
fulfilling different roles. Major properties of LTag include it helicase activity and its 
ability to bind host cell regulatory proteins like the retinoblastoma protein family, p53, 
pRb and others. These activities are important as they control cell function and undermine 
the infected cell’s destiny for apoptosis. Thus LTag controls both viral DNA replication, 
early and late gene expression, and interferes with host cell transcription factors. STag 
promotes cell cycle progression by associating with the catalytic (C) and structural 
subunits (S) of protein phosphatase 2A (PP2A) [85-86]. This interaction displaces the B 
subunit of PP2A resulting in inhibition of phosphatase activity [85-86]. Inactivation of 
PP2A in turn results in the activation of the mitogen-activation protein kinase [87]and 
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stress-activate protein kinase [88]pathways as well as pathways that use nuclear factor-κB 
(NF-κB), protein kinase C and phosphatidylinositol-3 kinase (PI-3 kinase)[88] . Most of 
the studies on STag have been performed with SV40 STag and mouse polyomavirus ST 
Ag, and it is assumed that BKV STag functions similarly. 
The late region of the genome is expressed efficiently only after viral DNA 
replication begins, although low levels of transcription of the late region occur early after 
infection as well. The late regions of these viral genomes encode the three capsid proteins, 
VP1, VP2 and VP2 (Figure 1.1B). As with early mRNA, late mRNAs are generated from 
a common pre-mRNA by alternative splicing. The coding regions of VP2 and VP3 
overlap, with VP3 sequences being a subset of VP2 sequences. The coding region of the 
N-terminus of VP1 overlaps that for the C-termini of VP2 and VP3, with translation of 
VP1 being from a different reading frame than VP2 and VP3. A fourth late protein called 
agnoprotein is also encoded by BKV. This 62-71 amino acid protein is encoded by the 
leader region of the late viral mRNA and accumulates in the perinuclear region during the 
late phase of the infection cycle. It was originally named agnoprotein because its function 
was unknown. It appears however, to facilitate the localization of the major capsid protein 
to the nucleus and may also enhance the efficiency with which virus spreads from cell to 
cell [80].  
The promoters and enhancers for transcription are located close to the origin of 
replication. Together, the promoters, enhancers and origin are referred to as the NCCR. 
Transcription extends bi-directionally from initiation sites near the origin, with early and 
late messenger RNAs (mRNAs) being transcribed from opposite strands of the viral 
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genome. Thus the early region extends form the origin to a site about halfway around the 
genome.   
 
 
(Adapted from Cubitt 2006 {Cubitt, 2006 #280}, 
http://www.brown.edu/Research/Atwood_Lab) 
 
Figure 1.1 Virion structure and genomic organization of BK virus.  
A. Representation of the structure of the BKV virion. Note that the shell is made up of 72 
pentamers of VP1. Twelve of these lie on icosahedral fivefold axes and are surrounded 
by five other pentamers. The remaining 60 pentamers are surrounded by six other 
pentamers  
B. Genomic map of BK virus Dunlop strain. The origin of replication (ori) and 
transcriptional regulatory region (NCRR) is at the top. The early region extends 
counterclockwise and the late region clockwise from the top. The regions encoding viral 
proteins are in black and the position of the intron in grey.  
A B 
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Life Cycle 
Interaction of a virus with its cell surface receptor is the initial step during 
infection of a host cell. In the case of BKV, the viral capsid VP1 interacts directly with 
α(2,3)-linked sialic acid to bind to and invade permissive host cells[81, 89]. The BKV 
viral receptor, α(2,3)-linked sialic acid, is believed to interact with the binding cleft 
between the BC1 and BC2 loops of the major capsid protein of BKV VP1. This 
speculation is based on the high structural similarity between VP1 of BKV and the 
crystallized VP1 proteins of mPy and SV40, which both bind to their receptors at their 
exposed BC loops [90-94].  
Like SV40, BKVuses caveolae-mediated endocytosis to be delivered to the ER for 
uncoating.  [95]. An acidification step is required once the virus is inside the caveolae.  
Lysosomotropic reagents that neutralize the pH of intracellular vesicles have been shown 
to prevent production of BKV viral proteins [95]. BKV’s entry into the nucleus has not 
been well described although it is believed to traffic through the Golgi to the ER and then 
accumulate at perinuclear regions [95-96]. 
Traditionally, basic research on BKV has been conducted using the African green 
monkey kidney cell line (Vero) which demonstrated a role for sialic acids, galactose, and 
polysialylated gangliosides as a receptor for BKV infection of Vero cells and in virus 
binding to red blood cells [97-99], as well as studies on viral trafficking. Most recently 
however a human proximal tubule epithelial (HPTE) cell culture system was developed 
to investigate BKV pathogenesis in human cells [100]. BKV’s receptor on these HPTE 
cells indicate a prominent role for the gangliosides GD1b and GT1b [81]. 
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The time course of infection by polyomaviruses primarily depends on two 
parameters: multiplicity of infection and growth state of the cell. Infection proceeds more 
rapidly at higher multiplicities of infection than at lower multiplicities. This most likely 
reflects the fact that critical levels of the viral early proteins are attained earlier when 
more viral genomes are available for transcription to produce the viral early mRNAs. The 
other critical parameter is the growth state of the host cell. At the same multiplicity of 
infection, viral DNA replication begins sooner, and the production of progeny virions is 
completed more rapidly when cells are growing exponentially than when cells are 
confluent and in a G0 state at the time of infection.  
The genome and life cycle of BKV has mostly been inferred from studies performed 
on SV40 and mouse polyomavirus. Therefore it is important that studies on BKV be 
carried out to determine more clearly how its individual proteins function in its life cycle 
as well as its role in disease. 
 
Route of transmission and seroconversion   
 BKV is known to be widespread in the human population, with more than 80% of 
the world population asymptomatically infected [101]. Most people are infected during 
childhood and up to 90 % of children between ages 5 and 9 are seropositve.  As people 
age, their antibody titers decrease [102-104].  The high incidence of BKV infection raises 
obvious questions about the mode of transmission from one individual to another. Given 
the known latency of the virus in the kidney, urine would appear to be a natural vehicle 
for spread within and between families via the urino-oral route. However specific studies 
on the early acquisition of BKV infection have not been done. BKV DNA has been 
 25
detected in nasopharyngeal aspirates, feces, blood, semen, genital tissues, tonsils, 
peripheral blood mononuclear cells (PBMC), and normal skin biopsies, hence it is 
possible that the virus may be transmitted by intimate contact with infected individuals. 
The possibility of feco-oral transmission has been recently raised by the demonstration of 
viral DNA in urban sewage[105]. Transplancental transmission of BKV from mother to 
fetus has also been evaluated however the data is conflicting and controversial [106-109]. 
Respiratory transmission cannot be ruled out since there is evidence of children with 
respiratory diseases showing high percentage of tonsillar tissues containing nonintegrated 
forms of BKV DNA [110]. In conclusion, transmission of BKV is currently not well 
defined.  Data shown in chapter 5 this dissertation suggests that BKV transmission may 
occur via the oral route.  
 
Pathogenesis, dissemination and persistence  
 BKV infection typically occurs during childhood, with or without mild respiratory 
symptoms, followed by a state of non-replicative infection in various tissues, with the 
urogenital tract as the principal site [111] 112].  BKV DNA has been detected in 30 to 
50% of healthy kidneys, primarily in within the cortex and medulla and to a lesser extent 
in the ureters [113-114]. 
BKV DNA has also been found in several other cell types including cervix, vulva, 
prostate, semen and brain tissues [114-119], as well as in peripheral blood mononuclear 
cells (PBMC) and spleen [101, 117, 120]. It is possible that PBMCs may play a role in 
persistence and dissemination of BKV in the human host. While BK DNA sequences 
have been widely detected in many cells types, its replication and pathogenesis have only 
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been studied within the kidney cell.  Chapter 5 of this dissertation explores the potential 
for BK permissive infection in the salivary gland cell. 
   
BKV-associated diseases  
It is not known whether BKV enters a latent state or maintains a low level of viral gene 
expression and replication within detected cell types and tissues, although intermittent 
replication must occur as evidenced by periodic excretion of virus in the urine. 
Approximately 5% of periodic immunocompetent individuals have BKV viruria as well 
as approximately 3% of pregnant women have asymptomatic viruria during the second 
and third trimesters [109, 121-123]. How the host innate, humoral and cellular immune 
responses control BKV persistent infection remains unknown.  
 
BKV in Immune suppression 
BKV-associated nephropathy (BKN) 
BKN has been described by Nickeleit et al as ranging from intranuclear viral 
inclusion bodies to necrosis with denudation of basement membranes within tubular 
epithelial cells, as a result of BKV replication [113]. Several investigators have studied 
and reviewed BKN and it has been determined that 1-9% of renal transplant recipients 
typically develop BKN post transplant [124-126] and of those patients with BKN up to 
80% result in graft loss [125, 127].  
The mechanism by which BKV reactivates in kidney epithelium of renal 
transplant recipients is poorly understood. While it has been suggested that immune 
suppression may play role in viral reactivation this is not always the case as nonrenal 
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solid organ transplant and other immunosuppressed patients do not develop BKN [112, 
128]. Other risk factors including patient age, gender, HLA mismatches, BKV serotype 
or type of immunosuppressive drug used may play a role in the development of BKN 
[127, 129-131].  
The definitive diagnosis of BKN requires allograft biopsy. One of the difficulties 
associated with biopsies as a diagnostic measure is sampling error due to the multi-focal 
characteristic of BKN. Typically a biopsy is accompanied by tests that detect the 
presence of decoy cells or virus infected cells shed in the urine and viremia [132]. Singh 
et al  has recently described a new method for diagnosing BKN by the detection of 
"Haufen" (after the German word for "cluster or stack") or clusters of BK virions via 
electron microscopy in voided urine [133]. 
 Currently there is no approved treatment for BKN. Typically the level of 
immunosuppression is monitored and polyomavirus-inhibitory drugs such asCidofovir is 
administered. Cidofovir is an antiviral nucleoside analog which has been shown to be 
effective in treating BKN along with reduced immunosuppresion [134-136], however at 
high doses this drug has been shown to be nephrotoxic [137]. Retransplantation is another 
intervention option for BKN patients although there is the possiblity that disease 
manifestation will not re-occur.  
 
Hemorrhagic cystitis 
Another BKV-associated complication is hemorrhagic cystitis (HC) which occurs 
in more than 10% of bone marrow transplant (BMT) recipients [138-139]. HC diagnosis 
typically includes dysuria and viruria which occurs at about 2-12 weeks post 
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transplant[140-141] using both urine cytology and PCR detection of viral DNA [139] . 
BK virions can be detected in exfoliated epithelial cells and is thought to be caused by 
viral reactivation in the urothelium [142-143]. The onset and termination of viruria has 
been shown to correlate with the progression of HC {Ahsan, 2006 #196} [140, 144]. Like 
BKN, Cidofovir  is also being tested as a treatment option for HC patients[145-147].   
 
Human Immunodeficiency Virus 
 BKV viruria has been shown to increase in HIV positive individuals [148]with 
some groups showing increased viruria concomitant with a decrease in CD4+ T cell 
counts[149]. However, increased BKV viremia in HI- positive individuals has not been 
established [150-151]. In AIDS patients , BKV has been reported to cause fatal 
tubulointerstitial nephropathy, disseminated pulmonary infection, retinitis and 
meningeoencephlalitis[152-155] . Others have reported hemorrhagic cystitis similar to 
that observed in bone marrow transplant recipients [156-157].   
The effect of HIV proteins on BKV replication was investigated by Gorill et. al in 
vitro. It was demonstrated that HIV proteins Tat and Vpr dramatically stimulated BKV’s 
early promoter, BKV(E) transcription. Using both site-directed mutagenesis analysis and 
electrophoretic mobility shift assay (EMSA) Gorill et al showed that Tat activated 
BKV(E) by inducing binding of the NF-kappaB p65 subunit to kappaB motif at the 3’ 
end of BKV(E). In addition, this study identified a sequence within the 5’UTR of 
BKV(E), BKV(E)-TAR with homology to HIV-1 transactivation response (TAR) 
element. Using RNA EMSA assays, it was determined that Tat bound to BKV(E)-TAR 
while deletion of the BKV(E)-TAR sequence prevented Tat transactivation of BKV(E) 
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transcription.  Site-directed mutagenesis analysis of potential Tat-responsive 
transcriptional motifs complemented by an electrophoretic mobility shift assay (EMSA) 
showed that Tat activated BKV(E) by inducing binding of the NF-kappaB p65 subunit to 
a kappaB motif near the 3' end of BKV(E). In addition, a sequence within the 5' UTR of 
BKV(E) transcripts (BKV(E)-TAR) was identified that is identical to the HIV-1 
transactivation response (TAR) element. The BKV(E)-TAR sequence bound TAT in 
RNA EMSA assays and deletion of the BKV(E)-TAR sequence eliminated Tat 
transactivation of BKV(E) transcription. This data suggests that HIV Tat can positively 
regulate BKV(E) transcription by a dual mechanism which has huge implications for and 
is extremely important in BKV-associated diseases in AIDS patients [158].  
 
Autoimmune disease 
 BKV has been suggested to play a role in autoimmune diseases such as Systemic 
Lupus Erythematosus (SLE)[159-160] and Sjogren’s Syndrome (unpublished data). SLE 
is the prototype of systemic rheumatic syndrome and is characterized by production of a 
wide array of autoantibodies. The majority of these autoantibodies are directed against 
nuclear constituents or antinuclear antibodies (ANA). In patients with SLE, it has been 
suggested that BKV infection might initiate autoimmunity by inducing antibodies against 
DNA and histones [161-163]. Work performed by Christie et al [164] observed that 
rabbits inoculated with BKV particles produced antibodies directed to both viral 
structural protein and host histones [164]. In support of these findings, patients with BKV 
infection with expression of large Tag have also developed anti-DNA antibodies and anti-
BKV antibodies which cross react with DNA [162]. As previously described, SS is an 
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autoimmune disease of which its etiology is unknown. Several viruses have been 
implicated in playing a role in SS pathogenesis including EBV, CMV, HTLV, Hepatitis 
C, Picornavirus and most recently coxsakievirus [33, 165]. Studies in our lab have 
recently detected BKV within salivary glands of SS patients using PCR and 
immunohistochemistry (unpublished data).  
 Other polyomaviruses have also been implicated in autoimmune diseases, namely 
JC virus in multiple sclerosis [166]. Multiple sclerosis is an autoimmune disease in which 
the body’s immune response attacks a person’s central nervous system (brain and spinal 
cord) leading to demyelination. There are conflicting reports of JCV DNA and viremia in 
patients with MS: several studies report a lack of evidence for JCV infection in MS 
patients [167-168], while others have found JCV DNA sequences in the cerebral spinal 
fluid (CSF) of some MS patients but not in healthy controls [169-170]. 
 
BKV and Cancer 
Viruses of the Polyomavirinae family including SV40, BKV, MCV and JCV have 
been implicated in human carcinogenesis [42]. With advancements in technology, 
scientists have been able to detect viral DNA in tumor specimens with more precision. 
These advanced techniques may account for discrepancies observed between past reports 
of BKV in tumors and present studies.  BKV DNA has been detected as integrated into 
the genome and episomally from many different types of human tumors. Sites include 
bone, pancreatic islet cells, kidney, urinary tract, prostate and a wide variety of brain 
tissues [114, 171-177]. Some of the larger studies show data as follows: using Southern 
blot technique, BKV was detected episomally in 4/9 tumors of pancreatic islet cells and 
 31
19/74 brain tumors.[174]. Further work using PCR technique demonstrated BKV DNA in 
58/68 of brain tumors, 21/27 osteosarcomas, and 5/13 Ewing’s tumors, the same 
sequences were also found in 13/13 of normal brain tissue, 2/5 normal bone tissue and 
25/35 peripheral blood cells [178]. RT-PCR further showed that most of these samples 
also expressed BKVRNA. Since it is well known that BKV reactivation occurs during 
immunosuppression, the presence of BKV DNA was also investigated in tumors 
associated with immunosuppression such as Kaposi’s sarcoma (KS). Using Southern 
hybridization technique BKV DNA was detected in KS at a frequency of 20%.   
In most of the studies, the tumors expressed viral RNA and were positive for large 
Tag by immunohistochemistry.  In general,only small amounts of BKV DNA was 
detected in both human tumors and normal tissues, averaging fewer than one genome per 
cell. The low copy number of viral genomes suggests that the tumor cells were 
transformed by a ‘hit and run’ mechanism, that is, an autocrine-paracrine effect. For 
example, Tag expressing cells may be secreting growth factors resulting in the 
recruitment and proliferation of Tag negative cells. [179].  Although much work has been 
done involving the detection of BKV in human tumors, the causal link between BKV and 
cancer development has not been established. .  
 
Objectives 
 Diseases of the salivary glands and the resultant quantitative changes in saliva 
affect the homeostasis of the oral cavity causing significant morbidity and poor quality of 
life.  Further, HIV associated salivary gland disease has been associated with the 
development of malignancy.   As reviewed in the body of work above, there is little 
 32
known with regard to the role of etiologic agents in both HIV-SGD and SS.  Based on the 
epidemiology of HIV-SGD and its behavior we hypothesized that a DNA tumor virus 
may play a major role in the disease. As polyomaviruses are associated with salivary 
gland disease in experimental animals, the potential for their involvement in the human 
disease is significant.  Toward better understanding HIV salivary gland pathology and in 
search of a potential etiologic agent we pursued and achieved the following aims: 
 
1. To determine an etiologic association of DNA tumor virus with salivary gland 
diseases  
i. HIV-SGD  
 In patients clinically diagnosed with HIV-SGD, BKV genes and genetic products 
were consistently detected within salivary gland biopsies. In addition, BK viremia and 
viral shedding into oral fluids were detected in HIV-SGD patients. Thus, we have 
determined the presence of BKV infection in HIV-SGD and report for the first time that 
BK polyomavirus is associated with HIV-SGD.   
 
ii. Sjogren’s Syndrome 
Based on our results of consistently detecting BKV in HIV-SGD, we hypothesized 
that BKV may also play a role in a similar disease, SS. BKV DNA and protein expression 
were detected in a subset of SS patients. Further analysis of host cell de-regulation was 
investigated and a novel transcript MALAT-1, known to be up-regulated by BKV was 
also shown to be increased in SS, confirming that BKV may be playing a role in SS 
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disease pathology. Thus, we have determined the presence of BKV infection in SS and 
report for the first time that BK polyomavirus is associated with SS. 
 
2. To determine how BKV expression modulates host cellular gene expression 
 This study details the up-regulation of a malignancy-associated transcript 
(MALAT-1) by BKV in HIV-SGD, in a SGD transgenic mouse model and in vitro and is 
the first report of a mechanism for MALAT-1 regulation.  
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CHAPTER 2 
 
HIV-SALIVARY GLAND DISEASE IS ASOCIATED WITH BK VIRUS 
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ABSTRACT 
HIV associated salivary gland disease (HIV-SGD) causes significant morbidity in 
those immune-suppressed by HIV. Evidence detailing the epidemiology of HIV-SGD 
suggests the involvement of a viral opportunist in its pathogenesis yet the specific 
etiology of HIV-SGD remains unclear. To determine the role for an opportunistic virus as 
the etiologic agent of HIV-SGD, we hypothesized that HIV-SGD was a manifestation of 
primary infection or reactivation with a DNA tumor virus during immune suppression. 
Minor salivary gland tissue from HIV positive patients with HIV-SGD and from HIV-
negative individual control subjects was examined. Degenerative PCR, sequence 
analysis, reverse transcriptase PCR and immunostaining were used for virus 
identification and characterization. Real-time PCR was used to assay detection of BK 
shedding and viremia. While herpesviral sequences were not detected, Polyomavirus 
DNA was consistently detected in HIV-SGD, and sequence analysis confirmed BKV 
DNA. In 14/14 patients clinically diagnosed with HIV-SGD, BK viremia/shedding into 
oral fluids and/or BK viral gene products were detected within HIV-SGD tissue while the 
related Polyomaviruses were consistently negative. This is the first report of BK salivary 
gland tropism and shedding into oral fluids. We have determined the consistent presence 
of BKV infection in HIV-SGD and report for the first time that polyomavirus infection is 
associated with HIV-SGD.  
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INTRODUCTION 
          HIV associated Salivary Gland Disease (HIV-SGD) is characterized by 
enlargement of the parotid gland,  complaint of xerostomia in the absence of xerostomic 
agents or diseases, and by the development of both lymphoepithelial cysts and 
lymphoma[1]. HIV-SGD is AIDS defining in pediatric HIV infection affecting up to 47% 
of children worldwide [2]. Like Sjogren’s sydrome, HIV-SGD affects both major and 
minor glands.  HIV-SGD-induced lack of saliva production, predisposes affected 
individuals to rampant tooth decay, oral candidiasis and progressive periodontal disease. 
Histologically, HIV-SGD is characterized by hyperplastic intraparotid lymph nodes 
and/or lymphatic infiltrates within the salivary gland [3]. HIV-SGD is also a feature of 
diffuse infiltrative lymphocytosis syndrome (DILS). DILS in HIV-infected persons is 
characterized by a persistent circulating CD8+ lymphocytosis. This CD8+ oligoclonal 
lymphocyte expansion infiltrates multiple organs, including the salivary glands and may 
reflect a virus driven antigen- response [4].  
Thus far the search for the etiology of HIV-SGD has been inconclusive.  Some 
argue that HIV-SGD is caused by autoimmune deregulation pointing to increased 
epithelial metaplastic cells that may represent an exuberant reaction to HIV [5].  Others 
argue that immune dysregulation may manifest as autoimmune reactivity resulting in 
HIV-SGD [6]. Evidence alluding to an opportunist as an etiologic agent is embodied in 
epidemiologic data showing different rates of HIV-SGD in children (20-47%) versus 
adults (3-7.8%) [7]. Further, the incidence of salivary gland disease among HIV infected 
patients increased significantly following the introduction of highly active antiretroviral 
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therapy (HAART). The disease becomes apparent shortly after induction of HAART, 
reminiscent of opportunistic infections triggered by immune reconstitution [8]. 
Interestingly, a similar increase in the incidence of post HAART-linked HPV 
associated oral warts has been described [9].   Opportunistic DNA viruses are frequent 
etiologic agents of HIV-associated oral lesions including Epstein-Barr virus (EBV) 
associated hairy leukoplakia and Kaposi’s Sarcoma associated herpes virus linked 
Kaposi’s sarcoma. Viral infections such as EBV and HIV have been implicated in HIV-
SGD [10].  Polyomaviruses are also candidate contributory DNA tumor viruses, and 
include JC, BK and SV40 virus.   Polyomaviruses cause parotid gland enlargement in 
rodents [11].  Mouse polyomavirus was initially named parotid tumor agent, because of 
the high incidence of salivary gland carcinoma development [12-13] . In humans, the 
etiological role for these polyomaviruses has not fully been explored.  
Based on epidemiologic correlates and the link to lymphoma development, [14] 
we postulated that HIV-SGD was a manifestation of  DNA tumor virus infection. The 
objective of these studies was to seek candidate infectious etiologic agents.  We 
determined that while herpesviral gene products were not detected in HIV-SGD, 
polyomavirus nucleic acids/antigens were consistently detected.  BKV sequences and 
gene products were detected using BK specific reagents. Further, shedding was detected 
and homologous polyomaviral proteins expressed in mouse salivary gland disease 
displayed subcellular localization similar to HIV-SGD. Collectively, these studies 
underscore the potential for BKV to be a key etiologic agent in HIV-SGD development.  
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MATERIAL AND METHOD 
Patients, Animals and Sample Collection. 
HIV positive patients were recruited from UCSF oral medicine clinic or UNC hospitals 
Dental clinic or infectious disease clinic to participate in the IRB approved study.  
Venopuncture was performed and plasma isolated.  Minor salivary gland biopsies were 
performed, tissues were either paraffin embedded, snap frozen, or embedded in OTC. 
Polyoma T transgenic mice with salivary gland enlargement were FVB mice from 
Charles River Laboratories, Wilmington Mass were generated that express the MMTV 
long terminal repeat/PyV-mT((Ellies)).   Wild type mice on the comparable background 
were used as controls.  
 
DNA Isolation and Polymerase Chain Reaction .   
Tissues were pulverized and ultracentrifuged on a 4M guanidine isothiocyanate-cesium 
chloride step gradient as previously described (Webster-Cyriaque, 1998). Throat washes 
were pelleted, cellular content centrifuged and pellets were treated with Qiagen DNAeasy 
kit.  PCR amplifications were performed with 150-200 ng of DNA as previously 
described (Webster-Cyriaque. 1998) and primers specific for herpesviral terminase, DNA 
polymerase,  polyomavirus T antigen or GAPDH , with amplification proceeding for 38 
cycles. (Hargis, AM et al, 1999). Control DNAs were amplified from B958 (EBV), 
HCMV-infected HEL cells, and  BCBL-1  (KSHV) as well as 200 ng of salivary gland 
DNA samples.  ( Van Gorder et al, Bergsagel DJ).   
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Sequencing 
 Purification was carried out with ExoSap-IT reagent (USB, Cleveland, Ohio, USA) 
followed by direct sequencing of the large T antigen region using ABI Big Dye® 
terminator reagents (ABI) and an ABI PRISM 3730 DNA sequencer. Sequences were 
compared using NCBI Blast2 software \with EMBL entries for the polyomaviruses for 
BKV (NC_001538), JC virus, Ki, Wu and SV40 and analyzed using Seqscape® software 
v2.5 (Applied Biosystems).  3-5 separate amplification-sequencing assays were 
performed per sample. Phylogentic trees were drawn using the neighbor joining method. 
 
RNA isolation, cDNA, Reverse Transcriptase PCR 
 Paraffin Block RNA Isolation Kit was used for RNA extraction (Ambion)and genomic 
DNA was removed with DNase I using  DNA-free Kit (Ambion), according to the 
manufacturer’s instructions .  RNA quality was assessed spectrophometrically.  Reverse 
transcription was performed with SuperScript™ II (Invitrogen) Reverse Transcriptase Kit 
according to manufacuturer instructions. For both VP1 and Tag primer pairs, a no-
template control produced no signals, suggesting that primer-dimer formation and 
genomic DNA contamination effects were negligible. Amplification results were 
normalized to B-actin. Real time PCR was also carried out, gene expression values were 
normalized to the levels of β-actin transcripts, using the 2– C(T) method, and are 
presented as the changes (n-fold) in viral gene levels, with the levels in uninfected/mock 
samples arbitrarily set to 1. 
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BKV Amplification from Plasma and Saliva.  
BKV DNA amplification from plasma/saliva was performed in duplicate using Tag 
primers and ABI Prism 7000 and SYBER green PCR core reagents kit according to 
manufacturer’s instruction.  The threshold of detection was 3-5 copies of the BKV/JC 
virus plasmids/reaction. 15 copies of the respective plasmid was added to the reaction 
mixture to rule out inhibition of the PCR in negative results (Figure 3). Investigators 
performing the PCR analyses were blinded and PCR for viremia was carried out in two 
different laboratories. Quantitation was achieved by use of standard curve. The mean 
copy number in the plasma was 106 (range102-107).   
 
Immunohistochemistry 
 Frozen sections were cut from minor salivary gland (HIV-SGD and healthy control 
glands) and from mouse parotid glands (transgenic/wild type) for immunofluorescent and 
confocal analysis. Tissue sections were fixed, blocked, then stained with 1 antibodies 
targeted to Tag or p53 and stained with 2o FITC or lissamine rhodamine conjugated 
antibodies. Slides were Vectashield coverslipped (Vector Laboratories) then subjected to 
confocal microscopy. Formalin fixed sections were deparaffinized, and washed.  Slides 
were incubated in 3% hydrogen peroxide and blocked and incubated with 1 antibodies 
for Tag/VP1. DAKO LSAB+ peroxidase kit (DAKO Corporation) was used according to 
manufacturer's specifications.   
 
 
 
 55
RESULTS 
Polyomavirus DNA detected in HIV-SGD  
Bivariate analysis for HIV-SGD development in our population (n=271)  revealed 
that patients on HAART were 4.4 times more likely to develop HIV-SGD and persons 
with high levels of  HIV RNA (> 400)  were 3.1 times more likely to develop HIV-SGD 
(Figure 2.1A).  Both lymphocytic infiltration and increased disease incidence while on 
HAART are typical of immune reconstitution, implicating an opportunist in the genesis 
of HIV-SGD. Viruses are consistently detected in saliva, particularly Herpesviruses.   
Degenerative polymerase chain reaction (PCR) was used to detect novel sequences by 
exploiting highly conserved Herpesvirus and Polyomavirus regions.  Highly conserved 
Herpesvirus terminase and polymerase regions were amplified [15-16]. The herpes 
terminase/polymerase genes were detected in cell lines infected with EBV, CMV and 
KSHV. Herpesviral DNA was not detected in 3/3 HIV-SGD patients shown (Figure 
2.1B). A viral microarray containing multiple open reading frames from each of the 
known human Herpesviruses and of high/low risk papillomaviruses failed to detect 
expression of viral genes in HIV-SGD tissue (Data not shown). Immunohistochemical 
(IHC) studies of these tissues did not detect EBV and KSHV viral proteins (Data not 
shown).  
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A. 
 
 
 
B. 
 
 
 
Figure 2.1. Detection of Polyomavirus DNA in HIV-SGD  and not Herpesviral DNA. 
A) Bivariate analysis for the development of HIV-SGD in our cohort suggests the 
involvement of an opportunist. B)  Control cell lines infected with the herpes viruses: 
EBV-infected B958 cells, CMV-infected HEL cells and KSHV-infected BCBL1 cells, 
lanes 4-6 respectively, were readily amplified in this highly conserved terminase region 
but Herpesviral DNA was not detected in HIV-SGD by degenerate PCR as shown by the 
lack of bands in lanes 1, 2 and 3. 
 
 57
C. 
 
 
 
D. 
 
 
Figure 2.1 (continued). C)  Polyomavirus DNA was detected by degenerate PCR in 
HIV-SGD lanes A and C but not in an HIV patient without the disease, lane B. D) 
Sequence analysis confirmed the detection of Polyomavirus DNA in HIV-SGD. 
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Degenerative nested PCR targeted to polyomavirus T antigen (Tag) region  
detected polyoma DNA in minor salivary glands in  2/2 of the HIV-SGD subjects (Figure 
2.1C lanes A and C), but not in a subject who was HIV positive without the disease 
(Figure 2.1C lane B). Viral gene products of expected size, were cloned and sequenced 
(Figure 2.1D).  Comparisons of amplified regions to known genomes detected 96-99% 
homology with the Tag regions of SV40, BK and JC viruses. In all, 14 HIV-SGD minor 
salivary glands and 10 control minor salivary gland tissues were selected for evaluation 
(Figure 2.2A).   A correct size BKV Tag product was consistently obtained in 11/14 
samples, while salivary glands from control patients were consistently negative.  These 
14 HIV-SGD samples were consistently negative for SV40(Figure 2.2A) and JC virus 
(data not shown). Multiple pairwise alignment of DNA sequences from the majority of 
HIV-SGD subjects revealed complete (99%) homology with the BKV MM (shown), Sau 
3, PittNP4 and Dunlop strains confirming BKV presence (Coordinates 1206-1377 shown 
in Figure 2.2B).  These sequences were consistently different from SV40, JC and the 
newly described human polyomaviruses  
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A. 
 
 
 
 
 
 
Figure 2.2  Detection of BK virus in HIV-SGD. Amplification from minor salivary 
glands of HIV-SGD and HIV negative persons with virus specific primers.  A) SV40 was 
not detected in HIV-SGD (SGD 1-14), BKV was consistently detected in HIV-SGD but 
BKV was not detected in minor salivary glands of HIV negative persons (SG 1-10). (+) 
positive control H2O, negative water control. 
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B. 
 
 
 
BKV TAg (-0.0002)
HIVSGD 11 (0.0475)
HIVSGD 13 (0.2074)
KI T Ag  (0.1897)
WU T Ag  (0.2194)
JC T Ag (0.2062)
SV40 T Ag (0.2561)
HIVSGD 8 (0.0389)
HIV SGD 2 (-0.0001)
HIVSGD 10 (0.0000)
HIVSGD 14 (0.0000)
HIVSGD 3 (0.0000)
HIVSGD 12 (0.1398)
HIVSGD 5 (0.0000)
 
 
Figure 2.2  (continued). B) Sequence alignment of HIV-SGD PCR products from minor 
salivary gland tissues matched the highly conserved Tag region of  BKV but not SV40, 
KI, WU or JC. Phylogenetic analysis of sequences form HIV-SGD showed a high degree 
of relatedness to BKV and not to the other polyomaviruses, WU and KI. Neighbor 
joining analysis determined the phylogenetic relationship of HIV-SGD sequences to 
BKV.   
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BKV gene products detected in HIV-SGD 
To determine the state of infection within HIV-SGD, amplification of non-
structural and structural BKV transcripts were performed. RT-PCR of RNA from HIV-
SGD minor salivary glands detected STag and VP3 in 4 out of 4 diseased patients. 
Mucous retention cysts (ranula) from HIV negative persons were consistently negative as 
were the no RT controls (not shown). BKV transfected Vero cells were used a positive 
control (Figure 2.3A).   The histologic expression of BKV proteins was examined in 
HIV-SGD   (Figure 2.3B).  The absence of viral protein expression would be strong 
evidence against the role for BKV in the etiology of the disease. Immunofluoresence and 
confocal microscopy, detected Tag and its binding partner p53 within HIV-SGD.  
Immunofluorecence using both T ag monoclonal and T ag polyclonal antibodies 
determined punctuate perinuclear stain in 4/4 HIV-SGD patients and lack of staining in 2 
of the 2 HIV negative individuals (Figure 2.3B polyclonal shown).  p53 specific 
monoclonal and polyclonal antibodies detected distinct intracellular nuclear/perinuclear 
punctuate staining  in  4/4 HIV-SGD patients and not  in HIV negative subjects (Figure 
4C, monoclonal shown).  Confocal microscopy detected p53 and Tag 
cytoplasmic/perinuclear co-localization within HIV-SGD epithelial cells but not in 
control glands.  
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Figure 2.3. Detection of BKV gene expression in HIV-SGD.  A) Detection of 
structural, VP3 and nonstructural, STag BKV transcripts in HIV-SGD and in BKV 
transfected Vero cells at 24h (VBKV24H) but not in mucous retention cyst, ranula from 
healthy persons.  
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B. 
 
 
 
 
 
 
 
 
Figure 2.3 (continued). B) Immunofluorescense detects T ag in HIV-SGD subjects 1,2,5 
and 6 (polyclonal- red) but not in HIV negative (healthy) subjects SG3 and SG4. p53 
(green)(mouse monoclonal-green).  Tag and p53 colocalization are also detected in HIV-
SGD (yellow).   
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A. 
 
B. 
 
Figure 2.4.  Detection of BKV viremia and shedding in oral fluids of HIV-SGD.   A) 
qRT-PCR detects elevated BKV levels in the plasma of subjects with HIVSGD (n=14), 
but not in HIV negative subjects (n=6).  B) qRT-PCR detects elevated BKV levels in the 
oral fluids of subjects with HIV-SGD (n=11), but at much lower levels in HIV positive 
subjects (n=46) without salivary gland disease and in HIV negative subjects (n=12).   
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BKV DNA detected in blood and oral fluids of HIV-SGD 
BKV shedding and viremia were analyzed in HIV-SGD patients.  BKV plasma 
levels, as measured by quantitative real time RT-PCR, were found to be significantly 
higher in patients harboring the disease.  Plasma samples were obtained from HIV-SGD 
patients within six months of the HIV-SGD diagnosis.  In 9 out of 14 patients, the time at 
which BKV DNA was detected in plasma coincided with the histologic diagnosis of HIV-
SGD (Figure 2.3A). Plasma levels in persons with HIV-SGD ranged from 102 to 106 
copies/ml. It is expected that immune suppression itself would increase the opportunity 
for viremia.  Interestingly, in 17 HIV positive, SGD negative patients analyzed in a 
previous study of our cohort no BKV DNA was detected in plasma [17].  Plasma samples 
from six HIV negative samples did not exhibit viremia (Figure 2.3A).  Salivary shedding 
was also assessed.  While mean BK copy number for HIV-SGD was approximately 5,000 
(n=11), those who were HIV positive without the disease (n=46) or were HIV negative 
had mean BK copy numbers that were significantly lower.  
 
DISCUSSION 
 Establishment of HIV-SGD etiology may be based on the model offered by 
Fredericks and Relman of molecular guidelines for establishing causation which states 1) 
that nucleic acid sequence belonging to a putative pathogen should be present in most 
cases of infectious disease 2) that fewer/ no nucleic acid sequences should occur in hosts 
and tissues without disease 3) tissue sequence correlates, mRNA and protein, should be 
sought at the cellular level; and (4) sequence-based forms of evidence for causation 
should be reproducible [18]. 
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  Consistent with this model we have provided evidence that BKV is associated with 
the pathogenesis of HIV-SGD.    BKV DNA and gene products were detected in most 
cases of HIV-SGD and these gene products were not detected in salivary gland tissues 
from hosts not harboring the disease.  Degenerate PCR did not detect herpes viral DNA 
in HIV-SGD.  Nor were herpesviral transcripts detected by viral microarray, or EBV 
LMP1 or KSHV LANA detected by immunohistochemistry.  Lack of Herpesviral 
protein/transcript detection in HIV-SGD makes etiologic association doubtful.  This 
observation is further supported by the literature.  EBV did not have a pathogenic role in 
HIV-SGD lesions in the pediatric age group [19].   We and others have determined that 
CMV and HHV-8 were not associated [20].  Counter to the lack of detection of herpes 
viruses in the disease, one report consistently detected the EBV LMP 1 protein in HIV-
SGD, but the cytoplasmic membrane protein was only detected in the nucleus  perhaps 
demonstrating cross reactivity with a nuclear protein [10].  The Rivera study also 
detected HIV in the ductal epithelium of HIV-SGD which we have confirmed (data not 
shown).   HIV itself does not appear to be sufficient for HIV-SGD development.   
The etiologic role for polyomaviruses in human tumors and disease remains 
debated despite reports that demonstrate polyomavirus nucleic acid and protein [10, 21-
22].  In this study, Polyomavirus DNA was detected by degenerate PCR and was 
confirmed by sequence analysis.   While SV40 and JCV DNA were not detected, BK 
specific primers consistently detected BKV in HIV-SGD. Sequence analysis confirmed 
BKV’s presence.    Detection of BK structural and non structural transcripts within 
diseased tissue coupled with the detection of plasma viremia and oral shedding in the 
majority of subjects suggested that HIV-SGD was a manifestation of BK productive 
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infection.  Immunofluorescent studies of affected labial minor salivary gland tissue in 
HIV-SGD consistently demonstrated a nuclear/perinuclear punctuate staining pattern of T 
antigen with virus specific monoclonal and polyclonal antibodies as previously described 
[23]. In HIV-SGD p53 co-localized with BKV Tag oncoprotein.  Collectively, these 
results argue that BKV may be an etiologic agent in the pathogenesis of HIV Salivary 
Gland Disease.   
Our results, taken together with the epidemiologic correlates of the disease, have 
led us to develop a model in which we postulate that during childhood BKV is acquired 
by primary infection (Figure 2.5). HIV-SGD is closely linked to pediatric HIV with an 
incidence of 10%-47% 7,[24]. Subsequent to immune suppression a child may develop 
HIV-SGD and associated morbidity.  Healthy children may undergo sub-clinical BKV 
infection and not clinical salivary gland disease upon primary infection. BKV 
reactivation, perhaps from the uroepithelium [25], resulting in HIV-SGD. An adult 
however may experience primary infection or immune suppression-associated and its 
associated morbidity. The presence of HIV-SGD has been associated with favorable 
prognosis with regard to HIV disease progression [26].  Thus, we hypothesize that the 
significant local host immune response and lymphocytic infiltration in diseased salivary 
glands may imply that the host is capable of mounting a virus specific antigen-driven 
response.  This may indicate that the host is able to respond to other viral infections as 
well, slowing AIDS progression. 
These data support the hypothesis that BK plays a role in the etiology of HIV-
SGD.  Elucidating a potential etiologic agent and beginning to dissect the pathogenesis of 
HIV-SGD is the first step toward treatment of this emerging disease.   
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Figure 2.5.  Proposed Role for BKV as an infectious agent in the development of 
HIV-SGD. 
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CHAPTER 3 
 
BK VIRUS DETECTED IN SALIVARY GLANDS OF SJOGREN SYMDROME 
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ABSTRACT  
Sjogren’s syndrome (SS) is a chronic autoimmune disease characterized by 
lymphocytic infiltration of the exocrine glands, especially the lacrimal and salivary 
glands. Although SS was first described in the late 1800’s, the etiologic agent is still 
currently unknown. It has been hypothesized that a persistent viral infection may drive 
the autoimmune response, however the identity of that virus has remained elusive. The 
aim of this study is to test the hypothesis that polyomavirus BKV may play a role in SS 
disease. Minor salivary gland tissue from SS patients and from healthy individual control 
subjects was examined. Degenerative PCR, sequence analysis and immunostaining were 
used for virus identification and characterization. BKV polyomavirus DNA was detected 
in a subset of SS patients and confirmed by sequence analysis. In 2/7 patients clinically 
diagnosed with SS, BK DNA and protein expression were detected within SS minor 
salivary gland tissue and not in healthy individuals. A transcript, metastasis associated 
lung adenocarcinoma transcript 1 (MALAT-1) known to be up-regulated by BKV was 
also shown to be increased in SS, confirming that BKV may be playing a role in SS 
disease pathology. We have determined the presence of BKV infection in a subset of SS 
and report for the first time that BK polyomavirus may be associated with SS disease.  
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INTRODUCTION  
 Sjogren’s syndrome (SS) is a chronic immune-mediated inflammatory disorder 
characterized by lymphocytic infiltration of the exocrine glands, especially the lacrimal 
and salivary glands, and by extraglandular manifestations in approximately 30% of cases. 
It is a systemic disease, with manifestations from several organ systems such as lungs, 
kidneys, skin, blood vessels and muscles, and a malignant lymphoproliferative disease 
may appear in approximately 5–10% of patients. It can occur in a secondary form (sSS) 
in association with various autoimmune diseases such as rheumatoid arthritis, systemic 
lupus erythematosus, systemic sclerosis, myositis and others, whereas in the absence of 
these conditions, the disease is classified as primary SS (pSS).  
  One of the hallmarks of the syndrome is B cell hyperreactivity that is manifested 
by hypergammaglobulinemia, circulating immune complexes, and multiple 
autoantibodies, such as anti-Ro/SSA and anti-La/SSB. Patients with anti-Ro 
autoantibodies may have a statistically significant increased incidence of parotid 
swelling, lymphadenopathy, respiratory symptoms and lymphoma [1]. Salivary gland 
epithelial cells have long been thought to play a central role in the pathophysiology of the 
syndrome, since they inappropriately express class II major histocompatibility complex, 
adhesion and functional costimulatory molecules, proinflammatory cytokines, lymphoid 
chemokines, and autoantigens [2]. Despite better knowledge of the immunopathologic 
constituents of the syndrome, the etiology of this autoimmune response remains 
unknown. 
 It is believed that the etiology of SS consists of genetic, infectious, endocrine and 
psychoneuroimmunological factors. Several viruses, including EBV, CMV, HCV, 
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Coxsakievirus and retroviruses have been investigated as important co-factors in the 
development of SS [1]. However, the data regarding theses viruses as a causative agent 
for SS are contradictory and remains to be established. Recently our group has detected 
polyomavirus DNA, RNA and protein expression in a related salivary gland disease, 
human immunodeficiency virus-associated salivary gland disease (HIV-SGD).  Using 
polymerase chain reaction, sequencing and immunohistochemistry techniques, we report 
for the first time that patients with SS harbor a potential polyomavirus infection in their 
minor salivary glands (MSG).  
Additionally, in previous work performed in our lab we observed BKV-mediated 
up-regulation of a novel non-coding RNA, MALAT-1 in HIV-SGD. Therefore we 
investigated the expression of MALAT-1 in SS. Using quantitative real-time PCR we 
detected up-regulation of MALAT-1 in two SS patients that were consistently positive for 
BKV DNA and protein expression.  
We therefore propose a hypothesis for the role of BKV in the generation of SS 
autoimmune disorder.  
  
MATERIALS AND METHODS 
Patient Sample Collection  
Minor salivary gland biopsies were collected from Sjogren’s syndrome diagnosed 
patients from UCSF oral medicine clinic. Tissues were either paraffin embedded or 
frozen and sectioned for histological analysis. Paraffin-embedded ranula tissue from 
healthy patients were obtained from the AIDS clinic at UNC hospital in an IRB approved 
protocol. 
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DNA Isolation and Polymerase Chain Reaction 
 DNA extractions were performed for seven SS samples, three ranula samples and BKV-
transfected Vero cells at 24 and 48hrs post-transfection using Qiagen DNeasy extraction 
kit modified for paraffin embedded tissue and Viral DNA extraction kit. Single stranded 
DNA oligonucleotides were synthesized for PCR primers using a published consensus 
sequence in the polyomavirus large T antigen gene [3].  
 
Sequencing  
Purification of PCR amplicon was carried out with ExoSap-IT (USB) reagent followed 
by direct sequencing of the large T antigen region using ABI Big Dye® terminator 
reagents and an ABI PRISM 3730 DNA sequencer (Applied Biosystems, Foster City, 
CA). Sequences were initially compared using Vector NTI software with EMBL entries 
for polyoma viruses for BKV (NC_001538), SV40, JCV, WU and KI. 
 
Immunohistochemistry 
Sectioned paraffin-embedded SS tissue on slides were used to identify viral proteins in 
the affected cells. Kidney tissue sections were used as a positive control for BKV 
infection. Sections were blocked in protein blocking serum, stained with primary 
antibody targeted to LTag and VP1 then stained with the DAKO LSAB+ peroxidase kit 
according to manufacturer’s specifications. Slides were counterstained with hematoxylin 
then mounted on coverslips using Permount. 
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RNA Isolation 
RNA was extracted from FFPET using a Paraffin Block RNA Isolation Kit (Ambion) 
according to manufacturer’s instructions. RNA pellets were washed in 75% ethanol and 
five of each sample pooled in 20 µL RNA Storage Elution Solution (Ambion). RNA was 
treated with DNase I using a DNA-free Kit (Ambion), according to the manufacturer’s 
instructions and the resultant RNA used for all further manipulations. RNA was stored at 
-80°C. 
 
Reverse Transcription 
Reverse transcription was performed with SuperScript™ II Reverse Transcriptase Kit. 
DNase treated RNA was mixed with 1.0 µL of random hexamer primers(300ng/ µL), 
dNTP(10mM) 1 µL and 9.0 µL of dH2O, heated for 5 minutes at 65°C, cooled on ice, and 
added to 4 µL  5x first-Strand Buffer and 2 µL 0.1M DTT, incubate at 25°C for  2 
minutes. Add to 1µL SuperScript™ II Reverse Transcriptase (RT) (Invitrogen), followed 
by incubation at 25°C for 10 minutes and denaturation at 72°C for 15 minutes. The 
resultant cDNA template was stored at -20°C. 
 
Real Time PCR 
PCR reactions were performed using an ABI Prism 7000 sequence detection system 
(Applied Biosystems) and the SYBR Green PCR Core Reagents kit (Applied Biosystems) 
in accordance to the manufacturer’s protocol. Briefly, 2ul of diluted cDNA sample was 
added to 13 µl of the PCR master-mix. The amplification included a 2-minute 50°C step 
and  an initial denaturation step for 10 minutes at 95°C, followed by 40 cycles consisting 
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of 15 seconds at 95°C and 1 minute at 60°C. Values were normalized using B-actin to 
correct minor variations in mRNA. 
 
RESULTS 
BKV DNA is detected in a subset of SS 
 The role of BKV in SS was investigated using PCR specific for the Tag region of 
BKV.  PCR detected BKV DNA in minor salivary glands in 2 of 6 SS patients tested 
(Figure 3.l, lanes 3 and 6). BKV transfected Vero cells were used as a positive control 
and non-transfected Vero cells as a negative control (Figure 1, lanes 7,8 and 9). Viral 
gene products were detected at the expected size, 174 bp and were sequenced in order to 
confirm the presence of BKV DNA in the disease (Figure 3.2).  The region that was 
amplified was compared to known polyoma genomes and was compatible with the T 
antigen regions of BK virus with 96-97% homology.    
 
BKV gene expression in a subset of SS  
 To determine the state of infection within the diseased tissue we examined the 
expression of viral proteins VP1 and Tag in the SS samples, histologically (Figure 3.3).  
The absence of viral protein expression would be strong evidence against the role for 
BKV in the etiology of the disease.  Immunohistochemical (IHC) studies were performed 
that revealed the expression of VP1 and Tag in the acinar epithelial cells of the lesions.  
Interestingly both proteins were localized to the nucleus. Figure 4 shows sections probed 
with monoclonal and polyclonal T ag antibodies (rows 1 and 2), VP1 antibody (row 3)  
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Figure 3.1 BKV DNA detected in a subset of SS patients. PCR amplification of BKV 
specific T ag DNA in six samples of SS MSGs. Note that patient 4B and 7B SS samples 
were positive (lanes 3 and 6) and non-transfected Vero cells were negative (lane 7), while 
BKV-transfected Vero cells were used as positive controls ( lanes 8 and 9). Arrow points 
to 100bp marker. 
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Figure 3.2. Sequence analysis confirmed the detection of BKV DNA in SS. Sequence 
alignment of SS PCR products from minor salivary gland tissues matched the highly 
conserved Tag region of BKV but not SV40, KI, WU or JCV. Neighbor joining analysis 
determined the phylogenetic relationship of SS sequences to BKV. 
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and isotype matched control antibody (row 4). BKV infected kidney cells were used as a 
positive control. Arrows point to positive stained cells in kidney cells as well as patients 
4B and 7B. No signal was detected in patient 2A. Taken together, the detection of viral 
DNA and protein expression of non-structural and structural gene products within 
salivary glands of SS patients suggest that BKV may play an important role in SS disease 
pathology.     
 
Up-regulation of a novel non-coding RNA, MALAT-1 in a subset of SS  
 We have previously detected BKV-mediated up-regulation of MALAT-1 in a 
similar disease, HIV-SGD (unpublished data, Chapter 4). Quantitative real-time RT-PCR 
was used to measure MALAT-1 levels in biopsied salivary glands of SS patients. The 
results showed that MALAT-1 was up-regulated five fold in patient SS7B which has 
been consistently positive for BKV genome and its gene products (Figure 3.4). Levels of 
mRNA expression is compared to negative control non-transfected Vero cells which is 
arbitrarily set as 1.   
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Figure 3.3 BKV gene expression in a subset of SS. Immunohistochemical staining for 
BKV structural and non-structural proteins. Monoclonal and polyclonal T ag-specific 
antibodies and polyclonal capsid protein VP1 antibody BKV proteins within the nucleus 
of minor salivary gland (MSG) epithelial cells in  patients 4B and 7B and not in patient 
2A with  Sjogren’s syndrome (SS). BKV-infected kidney cells were used as a positive 
control. Red arrows indicate BKV positive cells.  
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Figure 3.4. Up-regulation of a novel non-coding RNA, MALAT-1 in a subset of SS.  
MALAT-1 transcript levels in SS patient MSGs as measured by quantitative real-time 
RT-PCR was 5 fold higher in patient 7B compared to negative control non-transfected 
Vero cells which is arbitrarily set to 1, and 2 fold higher than positive control, BKV-
transfected Vero cells. Red arrows indicate SS patients positive for BKV DNA and 
protein. 
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DISCUSSION 
It has long been suggested that many autoimmune diseases represent pathologies 
induced by various viral agents [4]. However, this association has been fairly vague until 
now. We report here for the first time that the MSGs of patients with SS are potentially 
infected with a polyomavirus, BKV. The consistent detection of BKV’s genome and non-
structural and structural capsid protein in 2 of 7 patients with SS, and none of 3 controls 
(data not shown) is evidence for an association of BKV infection with SS. Such an 
association between BKV and SS has not previously been reported. 
Amplification products of the Tag from patients 4B and 7B were 96–97% 
identical to SAU-3 BKV isolate Tag. BKV has previously been linked with 
autoimmunity, specifically systemic lupus erythmatosus (SLE). SLE is the prototype of 
systemic rheumatic syndrome and is characterized by production of a wide array of 
autoantibodies. The majority of these autoantibodies are directed against nuclear 
constituents or antinuclear antibodies (ANA). In patients with SLE, it has been suggested 
that BKV infection might initiate autoimmunity by inducing antibodies against DNA and 
histones [5-7]. Using PCR, Sundsfjord et. al[8] identified BKV genomic sequences in 
16% of 44 patients with SLE. In another study, 60% of SLE patients showed at least one 
or several episodes of BKV reactivation while control groups did not have any viral 
replication[9]. Similarly, several other investigators reported reactivation of 
polyomavirus in patients with auto-immune diseases including SLE[10-11]. 
Detection of the main antigenic capsid protein VP1 is evidence against the 
possibility of persistent latent BKV RNA in the MSGs of patients with SS, while it favors 
the presence of potentially actively replicating BKV. The hapten-carrier model is most 
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commonly used to describe how viruses can induce autoimmune diseases such as SS or 
SLE. Viral proteins can form complexes with cellular chromatin and when released 
outside of the cell either upon virus-induced cell lysis or killed by CD8+ T cells, becomes 
bound by DNA-specific B cells which subsequently process and present peptides derived 
from both the viral protein and for example histones. This may be sufficient to transform 
B cells to anti-DNA antibody-producing plasma cells and to terminate histone-specific T 
cell anergy. Termination of T cell anergy may occur as a result of activation of virus-
specific CD4+T cells which start to secrete IL-2 into the microenvironment. IL-2 may 
then induce proliferation of histone-specific T cells which may terminate the anergic state 
of these autoimmune T cells.  
Previous work from our lab has determined that BKV infection of patient MSGs 
and salivary gland cells in vitro result in up-regulation of a novel non-coding RNA, 
MALAT-1 (unpublished date, Chapter 4).  Similarly, SS patients that were positive for 
MSG BKV infection also showed up-regulation of MALAT-1. MALAT-1 is widely 
expressed in normal tissue and while little is known about its function, appears to be a 
potentially generic marker for epithelial carcinomas [12-17]. MALAT-1 has been found 
to be up-regulated in lung adenocarcinoma metastasis [13], endometrial stromal sarcoma 
of the uterus [15] and non-hepatic human carcinomas [14]. MALAT-1 up-regulation has 
also been shown to be a predictor of unfavorable osteosarcoma drug therapy outcomes 
[12]. This initial description of MALAT-1 up-regulation by BKV in SS is of significant 
interest and importance because there is evidence that SS patients have a higher risk of 
developing malignancies such as cervical, lung and breast cancer [18, 19 ,reviewed in, 
20]. However, further work needs to be done to ascertain not only the precise underlying 
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mechanisms behind the increased risk of cancer in SS but also the significance of 
increased MALAT-1 expression in SS. 
Although great advances have been made over the past years in understanding the 
mechanism of SS disease to provide better therapies, their etiologies are largely 
unknown. We report here for the first time an association of BKV infection with SS, a 
finding that may lead to development of novel therapeutic strategies for autoimmune 
disorders. 
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CHAPTER 4 
 
BK VIRUS UP-REGULATES A NOVEL NON-CODING RNA ASSOCIATED 
WITH METASTASIS, MALAT-1 
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ABSTRACT 
 In this study it was determined that BK virus (BKV) oncoproteins up-regulate the 
novel non-coding RNA, metastasis-associated lung adenocarcinoma transcript-1 
(MALAT-1). While MALAT-1 is consistently up-regulated in several epithelial 
malignancies, little is known about its function or regulation.  MALAT-1 up-regulation 
was detected by suppressive subtractive hybridization (SSH) and quantitative real-time 
RT-PCR of BKV-infected minor salivary gland biopsies from HIV infected subjects with 
salivary gland disease (HIV-SGD). In a transgenic mouse model of salivary gland disease 
that expressed the homologous BKV oncoprotein, mouse polyoma middle T antigen, an 
increase in MALAT-1 transcription was detected in transgenic mice compared to wild 
type mice. Both wild type BKV infection and over-expression of BKV T antigen (both 
LT and ST) in vitro confirmed that these oncoproteins were responsible for up-regulating 
MALAT-1. These viral proteins functioned by increasing the activity of the MALAT-1 
promoter region. In conclusion, we have determined that BKV infection plays an 
important role in the regulation of MALAT-1 transcription. This study details the up-
regulation of a malignancy associated transcript by a DNA tumor virus and is the first 
report of a mechanism for MALAT-1 regulation.  
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INTRODUCTION 
BK virus (BKV) belongs to the polyomavirus family and is ubiquitous in the 
human population [1]. The viral genome consists of a closed circular double-stranded 
DNA molecule of approximately 5 kb encoding an early region, a late region and a 
regulatory region (RR) containing promoters, enhancers and the replication origin. The 
genome is transcribed bi-directionally from the origin, with the early region encoding for 
two non-structural proteins: large tumor antigen (LTag), and small tumor antigen (STag). 
The late region encodes for structural capsid proteins VP1, VP2 and VP3 and the non-
structural agnoprotien [1]. Transformation and oncogenicity induced by BKV is 
attributable to the viral oncoproteins, LTag and STag. LTag acts mainly by blocking p53 
and pRB family tumor suppressor protein functions and by inducing host cell 
chromosomal aberrations and instability [1]. The principal effect of STag is to bind the 
catalytic and regulatory subunits of the protein phosphatase PP2A, thereby constitutively 
activating the β-catenin pathway which drives cells into proliferation [1]. The mouse 
polyoma virus middle T antigen (MT ag) is functionally homologous to BKV ST ag and 
its over-expression results in salivary gland enlargement and pathology [1, Maglione, 
2001 #184].    
BKV DNA has been isolated in several human tumors, both integrated into the 
genome and episomally. Sites include bone, pancreatic islet cells, kidney, urinary tract, 
prostate and a wide variety of brain tissues [2-9]. Most recently our group consistently 
detected BKV within salivary gland tissues of HIV infected subjects and have determined 
that salivary gland cells are capable of productive BKV infection in vitro (Jeffers et al in 
press, Chapter 2, unpublished data).  
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Metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1) is a novel 
non-coding RNA. The MALAT-1 gene, also known as α gene, is found on chromosome 
11q13 and is well conserved among the mammalian species [10]. The MALAT-1 
transcript has been shown to localize to the nucleus [11] and currently has no known 
function except that its 3’ end can be processed to yield a tRNA-like cytoplasmic RNA 
[12]. MALAT-1 is widely expressed in normal tissue and while little is known about its 
function, appears to be a potentially generic marker for epithelial carcinomas [10, 13-17]. 
MALAT-1 has been found to be up-regulated in lung adenocarcinoma metastasis [10], 
endometrial stromal sarcoma of the uterus [15] and non-hepatic human carcinomas [14]. 
MALAT-1 up-regulation has also been shown to be a predictor of unfavorable 
osteosarcoma drug therapy outcomes [13].  
In this study, use of suppressive subtractive hybridization (SSH) demonstrated 
significant differential expression of MALAT-1 in HIV positive patients with salivary 
gland disease (HIV-SGD). Further, MALAT-1 was up-regulated in a MTag transgenic 
mouse model of salivary gland disorder, in an in vitro model of wt BKV infection, and in 
BKV LT and STag expressing cells. Finally, we provide strong evidence that the 
MALAT-1 promoter activity was up-regulated upon BKV oncoprotein expression, in 
vitro. Collectively, these data suggest a role for LT and ST antigen-mediated up-
regulation of MALAT-1.  
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Table 4. Genes up-regulated in HIV-SGD using suppressive subtractive 
hybridization.
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MATERIAL AND METHODS 
Subjects, animals and cell culture  
       Minor salivary glands (MSG) were dissected from the lower lips of 10 HIV-positive 
patients with SGD and from 7 healthy control subjects (with or without ranula) in IRB 
approved protocol at either the UNC University Hospital dental clinic or UCSF Oral 
AIDS Center. Biopsy samples were snap-frozen and kept in liquid nitrogen or formalin-
fixed and embedded in paraffin until the RNA extraction procedure.  
  Four MMTV/PyV-mT transgenic mice and four wild type mice parotid samples 
were kindly donated from Dr. Lesley Ellies.  
HSY cells are a neoplastic epithelial cell line initially established in culture from a 
human parotid gland adenocarcinoma [18]. HSY cells were obtained as a gift from Dr. B. 
Baum (NIH) and cultured in Dulbecco’s minimal essential medium (DMEM; Sigma).   
African monkey kidney cells or Vero cells (American Type Culture Collection [ATCC]) 
were cultured in DMEM (Sigma). All cell types were grown in medium supplemented 
with 10% fetal bovine serum (FBS) (Sigma), and 1% penicillin-streptomycin 
(pen/strep)(Gibco) unless otherwise stated and maintained in a humidified 370C, 5%CO2 
chamber. 
 
Suppression Subtractive Hybridization (SSH)   
  One to two µg of pooled biopsied salivary glands from HIV-SGD patients and 
pooled control (healthy  persons) RNA was sent to Evrogen (Russian Republic) for SSH. 
In brief, SMART technology was used to synthesize cDNA, which was subsequently 
digested with RsaI in preparation for subtraction in both directions (HIV-SGD as 
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driver/control as tester, and vice versa). Adaptors were ligated to the two cDNA 
populations, followed by two rounds of hybridization and amplification. The secondary 
PCR products from the two subtracted populations were then ligated into the pAL9 
vector. 
 
Sequencing of subtracted cDNA library           
Two hundred and fifty positive clones from each of the subtractions were 
randomly selected and cultured in 1.5 mL LB-medium in duplicate 96-well plates at 37 
°C overnight. Clones were selected by blue-white screening (Promega) and sequenced 
using a M13 forward promoter (-21) primer (5 -TGT AAA ACG ACG GCC AGT-3 ) 
and BigDye 3.0 sequencing mix (Applied Biosystems) before analysis by capillary 
electrophoresis on an ABI 3700 genetic analyser (Applied Biosystems). The sequences of 
the inserts of differentially expressed genes were identified using NCBI Blast search 
(blastn).  
 
RNA extraction and cDNA synthesis 
Total RNA was extracted from pooled MSGs of HIV-SGD patients, pooled MSGs 
of healthy controls, mouse parotid frozen tissues and Vero cells using RNeasy MiniKit 
(Qiagen,USA). Total RNA isolation from formalin fixed tissue using the Optimum FFPE 
RNA Isolation Kit (Ambion Diagnostics, INC) according to manufacturer’s instructions. 
The RNA was suspended in nuclease-free water and quantitated by UV 
spectrophotometry, aliquoted and stored at -80ºC. One µg total RNA from the HIV-SGD 
and control tissues, mice parotid tissue and Vero cells were reverse transcribed to cDNA 
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using random primers and the SuperScriptTM II Reverse Transcriptase (RT) Kit 
(Invitrogen) as described by the manufacturer. Contaminating DNAs were removed by 
use of RQ1 DNase kit (Promega) as described by the manufacturer. 
 
Northern Blot 
 Total RNA was isolated using TRizol (Invitrogen) as described by the 
manufacturer. Contaminating DNAs were removed by use of RQ1 DNase kit (Promega) 
as described by the manufacturer. 10 ug of RNA was subjected to electrophoresis and 
Northern blotting. MALAT-1 was hybridized with a 32P-labeled oligonucleotide probe 
for MALAT-1 
 
Semi-quantitative and quantitative real-time RT-PCR 
 Semi-quantitative RT-PCR was performed using previously published primers 
for Tag [19] and  Taq Polymerase (Qiagen, USA). The following program was used for 
amplification: 95˚C for 2 min (1x); 94˚C for 45 sec, 56˚C for 45 sec, 72˚C for 30 sec with 
2 sec increase per cycle (35x), 72˚C for 10 min (1x). Amplified cDNA was 
electrophoresed on 2% agarose gel (Sigma).   
Real time RT-PCR was performed with LightCycler 480 Syber Green I Master 
Mix in the presence of transcribed cDNA and 0.25mM of gene specific primers. 
Experiments were performed in duplicate and β-actin was used as an internal control.  
Duplicate or triplicate Ct values were averaged, normalized to an average β-actin Ct 
value, and fold activation in healthy vs diseased tissue was calculated using the 2-∆∆Ct 
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method. For Vero cells, gene expression values are presented as the changes (n-fold) in T 
Ag transcript levels, with the levels in non-transfected/mock samples arbitrarily set to 1. 
 
Immunofluorescence/Immunohistochemistry 
Frozen sections were cut from minor salivary glands (HIV-SGD and control 
glands) and from mouse parotid glands (transgenic and wild type) for immunofluorescent 
and confocal analysis. Tissue sections were fixed, blocked, then stained with either 
PAb416 (Genetex) antibody specific for SV40 T antigen or IgG isotype control. PAb416 
has been shown to cross react with BKV Tag and is commonly used for BKV Tag 
detection. Both antibodies were incubated with fixed cells for 1 hr at 370C followed by a 
fluorescencein-conjugated anti-mouse (Sigma) antibody (1:20). Slides were overlaid with 
Vectashield (Vector Laboratories) then subjected to confocal microscopy.  
Formalin fixed sections were deparaffinized, and washed.  Slides were incubated 
in 3% hydrogen peroxide and blocked and incubated with PAb416 (Genetex). DAKO 
LSAB+ peroxidase kit (DAKO Corporation) was used according to manufacturer's 
specifications.   
 
Plasmid cloning, transfection and infection 
A 5.5 kb region upstream of MALAT-1 transcription site was amplified using 
primers 5’GGGACGCGTAAAGAGGATTCTATCTAACAAGGA3’ and 
5’GGGCTCGAGGAAACGTGAAAACCCACTCT3’ and inserted into pSeap2-Basic 
expression cloning vector (Clontech) using restriction sites MluI and XhoI. To determine 
MALAT-1 promoter activity, Vero cells were first infected with BKV as previously 
 98
described (Jeffers et al, 2009, in press) with 64 HAUs of virus for 24 h. At 24 h post 
infection (hpi), virus was removed from the culture media, cells were washed with 1X 
PBS and replaced with fresh medium containing the MALAT-1 promoter plasmid and β-
gal construct plus transfection reagent. At stated times post transfection the cell 
monolayers or supernatant were collected for immunoblot assays, beta-galactosidase 
enzyme assay (Promega) or secreted alkaline phophatase enzyme assay (Promega) 
according to manufacturers instructions.  
For MALAT-1 transcript evaluation in vivo, Vero cells were transfected with 
pBKV35-1 plasmid DNA (ATCC 45026, MD). Following incubation at 37 °C for 24 h, 
48 h, or 72 h both untreated (mock) and transfected cells were harvested for RNA 
extraction and RT-PCR. 
 
Immunoblotting 
Total cell protein was extracted using 1% SDS lysis buffer (1% (w/v) SDS, 
0.05M Tris.Cl pH8, 1mM DTT). Protein concentrations were determined using the 
BioRad protein assay, and equal amounts of protein were electrophoresed on a 10% Bis-
Tris polyacrylamide minigel (Invitrogen). PAb416 (1:200) (Genetex) in 5% non-fat dry 
milk in 0.1% Tween-20 PBS (PBS-T) was used to detect T Ag expression and Actin (C-
11)-R sc-1615-R (1:1000)(Santa Cruz Biotechnology) in 1% BSA/TBS-T for actin 
expression. After washing in PBS-T/TBS-T, blots were probed with a horseradish 
peroxidase-conjugated secondary antibody (1:10,000) (Promega). Antibody complexes 
were detected using SuperSignal West Pico Chemiluminescent substrate (Thermo 
scientific) and exposed to film (Kodak). 
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Beta galactosidase enzyme assay 
 β-Galactosidase Enzyme Assay System with Reporter Lysis Buffer (Promega) 
was performed according to manufacturer’s instructions. Briefly, cells were collected, 
centrifuged and resuspended in1X lysis buffer and transferred in triplicate to 96 well 
plates. Diluted sample was added to an equal volume of Assay 2X Buffer, which 
contained the substrate ONPG (o-nitrophenyl-beta-D-galactopyranoside). Samples were 
incubated for 30 minutes, terminated by addition of sodium carbonate, and the 
absorbance read at 420nm with a spectrophotometer.   
 
Secreted alkaline phosphatase reporter gene assay, chemiluminescent 
 SEAP assay was performed according to manufacturer’s instructions. Briefly, 
culture supernatant from transfected or mock (untreated) cells were collected at stated 
times post-transfection. Collected sample was diluted 1:4 in Dilution buffer, heated at 
650C for 30 min then centrifuged at maximum speed to 30 s. Heat-treated samples were 
then transferred to a microplate (black or white), inactivated with Inactivation Buffer then 
treated with Substrate Reagent. Chemiluminescence was measured using a luminometer.  
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RESULTS 
Differential gene expression in HIV-SGD by SSH  
Differential gene expression in minor salivary glands from patients with HIV-SGD 
and healthy control subjects was examined with the use of SSH. Pooled RNA from ten 
HIV-SGD positive subjects and from seven HIV negative subjects was utilized to 
diminish individual variation. Two SSH libraries were constructed, disease (plus) and 
healthy library (minus).  The minus library was enriched for genes whose expression was 
suppressed in HIV-SGD and the plus library was enriched for genes whose expression 
was induced by disease development. 250 randomly selected clones were sequenced from 
the minus SSH library and 250 clones from the plus library; of those 232 and 208 
contained cDNA inserts , respectively.  The SSH library was automatically processed 
using a specifically created software tool. This processing included 3 basic steps: finding 
adaptor sequences on the 5’ and 3’ ends of a clone as markers and extracting a fragment 
from the clone, blasting the batch of fragments, clustering alignments and linking with 
unique gene identification. We were able to align 436 sequences with known or predicted 
human genes.  Our total number of alignments reached 502 due to 57 chimeric clones 
which had 2 or three clones from different RNA’s linked together during SSH.  Of the 
436 cDNAs 73 sequences were identified that did not match to any known or predicted 
mRNAs but aligned with the human genomic DNA and with EST databases. These were 
considered novel.  
 A non redundant set of the genes was created which excluded highly expressed 
clones present in both disease and healthy genes in the plus library.  There were 6 genes 
found more than once among sequenced SSH clones in each of the libraries (Table 1). It 
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was shown previously that a number of cDNA fragments corresponding to a gene in the 
SSH library correlates with a degree of differential expression of the gene [20]. 
Considering all of the differentially expressed clones detected by SSH analysis, major 
functional classes of transcriptionally regulated genes in minus library included signal 
transduction (9%), cell cycle(8%), immune/defense(8%), synthesis/ development/ 
differentiation (8%)  and transport (8%).  Transcriptionally regulated genes in the plus 
expression library included those involved in signal transduction (15%), 
synthesis/development/differentiation(13%), apoptosis(8%), metabolism(8%) and 
transport.   The largest category of de-regulated genes were unknown, among these was 
the metastasis associated lung adenocarcinoma transcript-1 (MALAT-1).  
 
MALAT-1 is up-regulated in Salivary Gland Disease 
To confirm the SSH data, quantitative real-time RT-PCR was performed using 
primers specific for MALAT-1. A 2.6 fold increase in MALAT-1 was detected in HIV-
SGD positive tissue compared to non-diseased tissue. Results were normalized to the 
levels of β-actin, using the 2– C(T) method, and are presented as the changes (n-fold) in 
MALAT-1 transcript levels. Non-diseased tissue samples were arbitrarily set to 1.  
A transgenic mouse model of salivary gland disease (SGD)  expressing mouse 
polyoma middle T antigen displays clinically observed salivary gland enlargement 
similar to HIV-SGD [21]. Mouse polyoma middle T antigen shares functional homology 
with small t antigen of the human BKV by complexing with c-src and pp2A [1]. Semi-
quantitative RT-PCR detected amplification of MALAT-1 cDNA from 4/4 transgenic 
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mice with SGD while the transcript was consistently detected at much lower levels in 4/4 
wild type mice (Figure 4.1B).  
 
BKV is detected in HIV-SGD 
 We have previously shown BKV consistently detected in HIV-SGD salivary 
gland biopsies (Chapter 2, unpublished data).  Further, BKV DNA was significantly 
increased in HIV-SGD patient serum and saliva (Chapter 2, unpublished data, Jeffers et 
al in press).   BKV Tag was detected within biopsied salivary glands of HIV-SGD 
subjects by immunofluorescence (representative image shown Figure 4.2A). 
Immunoflourescent studies of affected labial minor salivary gland tissue consistently 
demonstrated a nuclear/perinuclear punctuate staining pattern of T antigen with virus 
specific antibodies as previously described in prostate cancer [9, 22]. 
Immunohistochemical stains of paraffin embedded tissues consistently detect BKV Tag 
using a polyomavirus specific monoclonal antibody (Figure 4.2B). 
 
BKV up-regulates MALAT-1 in vitro  
Infection of a parotid salivary gland cell line, HSY, with BKV resulted in 
increased MALAT-1 expression by quantitative real-time RT-PCR (Figure 4.3A).  An 
increase in the 8.1 KB MALAT-1 transcript was detected in another BKV permissive cell 
line, Vero cells, by Northern blot analysis. U6 RNA was also probed as a loading control 
(Figure 4.3B).  To determine whether BKV Tag expression modulated MALAT-1 
transcription, both LT and ST antigen oncoproteins were over-expressed in Vero cells. 
Both semi-quantitative RT-PCR (Figure 4.3C) and quantitative real-time RT-PCR were  
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A. 
 
 
 
 
Figure 4.1. Up-regulation of MALAT-1 in salivary gland disease. MALAT-1 
transcript levels are elevated in salivary gland biopsies from A. HIV-SGD patients and B. 
an SGD mouse model. A. MALAT-1 transcript levels in human minor salivary gland 
biopsies were measured by quantitative real-time RT-PCR and found to be significantly 
higher in subjects diagnosed with HIV-SGD compared to healthy subjects without the 
disease. MALAT-1 amplified cDNA is shown for healthy (left panel) and diseased 
samples (right panel) in comparison to internal control, β-actin amplified cDNA.  
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B. 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 (continued) B. MALAT-1 transcript levels in mouse salivary gland biopsies 
were measured by semi-quantitative RT-PCR and found to be significantly higher in 
middle T antigen transgenic mice with SGD compared to wild type mice without the 
disease. MALAT-1 was amplified from a cDNA library of mouse SGD, shown are four 
diseased (left panel) and four wild type (right panel) mice compared to internal control, 
β-actin amplified cDNA.  
 
 
 
      1                 2                3                 1               2               3 
MTag transgenic mice Wild type mice 
1        2       3        4          1       2       3        4
T ag transgenic mice 
w/ SGD
Wild type mice
MALAT-1
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A. 
 
 
B. 
 
Figure 4.2. BKV detected in salivary gland biopsies of HIV-SGD patients. (A) 
Immunofluorescent staining showing BKV T ag protein (green) expression within 
salivary gland cells of HIV-SGD patients (left), IgG isotype control (middle) and HIV(-) 
patients (right). (B) Immunohistochemical staining of HIV-SGD salivary gland biopsies 
showing nuclear BKV T ag (arrows) expression and BKV infected kidney cells (right) as 
a positive control. 
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performed (Figure 4.3D). At 24 h and 48 h post-transfection an increase in MALAT-1 
transcript levels was observed using both techniques. By quantitative real-time RT-PCR a 
2.3 and 5.5 fold increase in MALAT-1 transcripts was detected compared to non-
transfected/mock Vero cells. Results were normalized to the levels of β-actin, using the 
2– C(T) method, and are presented as the changes (n-fold) in MALAT-1 transcript 
levels. Mock samples were arbitrarily set to 1 (Figure 4.3D). 
 
BKV infection upregulates MALAT-1 promoter  
 Upon determination that the MALAT-1 transcript was up-regulated in the 
presence of BKV Tag in vivo and in vitro, the effect of BKV oncoprotein expression on 
MALAT-1 promoter activity was investigated in the context of the whole virus. 
Examination of the enhancer/promoter region 5.5 kb upstream of the ATG start site using 
the PROMO 3.0, prediction of transcription sites program, detected many potential 
binding sites. The similarity of the sequence to the transcription binding site is greater 
than 98% (or dissimilarity of less than 2%).  Interestingly, numerous consensus binding 
sites were detected upstream of MALAT-1 start site consistent with the previously 
described activities of BK viral oncoproteins [23-25] including five p53 binding sites 
(green), three T antigen binding sites (red) , two TCF-2 sites (purple) and two E2F-1 sites 
(blue) (Figure 4.3A).  As described in the methods, 5.5 kb upstream of the MALAT-1 
coding region was amplified and cloned into a pSEAP expression vector. BKV infected 
Vero cells were transfected with the MALAT-1 promoter reporter construct.  Promoter 
activity was up-regulated 7 fold at 72 hours post-transfection of the cloned MALAT-1 
promoter. BKV T antigen expression within  
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Figure 4.3. BK virus up-regulates MALAT-1 transcript in vitro. (A) MALAT-1 
transcript levels in HSY cells as measured by quantitative real-time RT-PCR was 1.6 fold 
higher in BKV infected cells compared to uninfected/mock at four days post infection. 
(B) Northern blot analysis showing four fold increase in MALAT-1 transcript in Vero 
cells transfected with BKV DNA.  
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Figure 4.3. (continued). C) Amplified cDNA bands showing an increase in MALAT-1 
transcript in Vero cells expressing BKV LT/ST antigen compared to untransfected/mock. 
(D) MALAT-1 transcript levels in Vero cells as measured by quantitative real-time RT-
PCR was three and six fold higher at 24 h and 48h post transfection.  
 109
these cells was confirmed by immunoblot assay using a polyomavirus T ag specific 
monoclonal antibody (Figure 4.4B).  
 
DISCUSSION  
In this study we have shown that a novel non-coding RNA, MALAT-1 is up-
regulated by the human polyomavirus, BKV. While BKV is a known DNA tumor virus 
and has been implicated in a number of pathologies [2, 8-9, 19, 26-28], little is known 
with regard to BKVs modulation of host gene expression in disease.  However, 
differential gene expression studies described here determined that MALAT-1 was the 
most differentially expressed transcript in a BKV-associated salivary gland pathology, 
HIV-SGD.  
In a survey of normal tissues it was determined that MALAT-1 was expressed in 
numerous cell types, with highest relative expression in the normal pancreas and lung, 2.0 
and 1.6 fold respectively [10]. MALAT-1 is associated with epithelial cell malignancies 
including non-small cell lung tumors, stromal sarcoma and non-hepatic carcinomas. 
MALAT-1 expression is associated with a five-fold increased risk of subsequent 
metastasis in non-small cell lung tumors compared to low expressing tumors. In fact, in 
non-small cell lung carcinoma, MALAT-1 expression is an independent prognostic 
parameter for survival [10].  Further, high expression of MALAT-1 is also a negative 
predictor for osteosarcoma drug therapy outcome [13].  We show that MALAT-1 is up-
regulated in another epithelial disease, a BKV  
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Figure 4.4. BKV infection up-regulates MALAT-1 promoter activity.  A. 5.5 kb 
MALAT-1 promoter region (black) showing T antigen (red), p53 (green), TCF-2 (purple) 
and E2F-1 (dark blue) binding sites. MALAT-1 coding region is shown in light blue. B. 
MALAT-1 promoter activity was significantly increased in the presence of BK viral 
infection at 48 and 72 h post-transfection. Immunoblot showing BKV T antigen protein 
expression in cells infected with BKV. Antibodies against T Ag (top panel), β-actin 
(bottom panel) were used.  
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associated salivary gland pathology, HIV-SGD.  This initial description of MALAT-1 up-
regulation by this small DNA tumor virus is of significant interest and importance. 
The success of BKV and its related polyomaviruses as formidable DNA tumor 
viruses is attributable to expression of their T antigen oncoproteins.  The ability of LT 
and ST antigens encoded by human polyomaviruses to ablate p53 and pRb function and 
enhance pp2A signal transduction are well documented [23, 25, 29].  Mouse Polyoma 
MT antigen shares 79 amino acids that represent a DnaJ domain with both BKV LT and 
ST, as well as an additional 112 amino acids with BKV ST antigen[1]. Almost all of the 
sequence of BKV STag is contained within the MTag of mouse polyoma virus and both 
the mouse and human antigens form complexes with protein phosphatase 2A (pp2A) [30-
31].  
HIV-SGD is a polyomavirus-associated salivary gland pathology, in which BKV 
Tag was detected within acinar and ductal cells of the salivary gland (unpublished data, 
Chapter 2, Fig 2). MALAT-1 up-regulation was consistently detected in HIV-SGD.  To 
further confirm Tag-mediated MALAT-1 up-regulation in vivo, a mouse model of 
polyomavirus associated salivary gland disease was explored. Mice infected with 
polyomaviruses not only develop salivary gland disease but often go on to develop 
malignancies within the glands [21, 32].  A mouse polyoma middle T antigen-expressing 
transgenic model with SGD pathology was used [21].   Interestingly, MALAT-1 was 
highly expressed in transgenic animals expressing the functional homologue of the BKV 
oncoprotein compared to wild type animals.    
In vitro studies were also performed to confirm BKV’s role in MALAT-1 up-
regulation. Parotid gland cell lines were infected with BKV in vitro and transcript levels 
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monitored. At four days post infection relative MALAT-1 transcript levels were 1.6 fold 
as compared to uninfected/mock cells (Figure 3A). Considering that Ji et al, determined 
normal salivary gland cells express negligible MALAT-1 and that comparisons of 
MALAT-1 expression in non-metastatic and metasatic lung tissues reveal a 3 fold 
difference in expression levels[10], this 1.6 fold difference may potentially be 
biologically significant. Increased MALAT-1 transcripts were also consistently detected 
by quantitative real-time RT-PCR in HSY cells that were permissively infected with 
BKV (Figure 4.3A) or in Vero cells that over-expressed LT/ST antigen by Northern blot 
(Figure 4.3B), quantitative (Figure 4.3D) and semi-quantitative real time RT-PCR 
(Figure 4.3C).  The implication of the onco-RNA’s association with a DNA tumorvirus is 
significant. 
MALAT-1 has been consistently up-regulated in several epithelial malignancies 
hence its expression and detection are of significant biologic importance. In an initial step 
toward understanding how BKV regulates MALAT-1, a reporter assay was developed to 
assay activation of MALAT-1’s enhancer/promoter region. Upon BKV infection 
increased reporter activity was observed. Several potential binding sites for BKV Tag 
were detected within the enhancer/promoter region as well as p53 binding sites, TCF-2 
and E2F-1 sites. Further work would need to be done to determine which region within 
the 5.5kb length upstream of MALAT-1 binds specifically to BKV oncoproteins.  
In conclusion, we have demonstrated that MALAT-1 is up-regulated in both 
human and mouse salivary gland pathologies and that both these diseases are associated 
with T antigen oncoprotein expression. We also show that BKV LT and ST antigens can 
up-regulate MALAT-1 in vitro in two different cell types (salivary/kidney) either by 
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direct infection or over-expression of protein antigens. Lastly, we have shown that BKV 
infection can regulate MALAT-1 at the transcription level. Because of its strong disease 
association, it is critical to understand mechanisms by which MALAT-1 expression is 
enhanced.  Its modulation by the small DNA tumor virus BKV, is intriguing and opens 
the door toward understanding the regulation of this important malignancy associated 
gene.  
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CHAPTER 5 
 
BK VIRUS HAS TROPISM FOR HUMAN SALIVARY GLAND CELLS IN-
VITRO: IMPLICATIONS FOR TRANSMISSION 
 
The data from this chapter is reprinted with modifications from a published manuscript in 
Virology “LK Jeffers, V Madden and J Webster-Cyriaque, “BK virus has tropism for 
human salivary gland cells in vitro: Implications for transmission” 
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ABSTRACT 
In this study, it was determined that BKV is shed in saliva and an in-vitro model 
system was developed whereby BKV can productively infect both submandibular (HSG) 
and parotid (HSY) salivary gland cell lines. BKV was detected in oral fluids using 
quantitative real-time PCR (QRTPCR). BKV infection was determined using quantitative 
RT-PCR, immunofluorescence and immunoblotting assays. The infectivity of BKV was 
inhibited by pre-incubation of the virus with gangliosides that saturated the major capsid 
protein, VP1, halting receptor mediated BKV entry into salivary gland cells. Examination 
of infected cultures by transmission electron microscopy revealed 45-50 nm BK virions 
clearly visible within the cells. Subsequent to infection, encapsidated BK virus was 
detected in the supernatant. We thus demonstrated that BKV was detected in oral fluids 
and that BK infection and replication occur in-vitro in salivary gland cells.  These data 
collectively suggest the potential for BKV oral route of transmission and oral 
pathogenesis. 
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INTRODUCTION 
BK virus (BKV) belongs to the polyomavirus family and is ubiquitous in the 
human population [1]. The viral capsid is icosahedral and has a diameter of 45-50 nm. 
The genome consists of a closed circular double-stranded DNA molecule with 
approximately 5 kb. BKV genome consists of an early region, a late region and a 
regulatory region (RR) containing promoters, enhancers and the replication origin. The 
genome is transcribed bi-directionally from the origin, with the early region encoding for 
two non-structural proteins: large tumor antigen (T Ag), and small tumor antigen (t Ag). 
The late region encodes for structural capsid proteins VP1, VP2 and VP3 and the non-
structural agnoprotien [1]. BKV initially binds to its cell surface receptor, an N-linked 
glycoprotein or ganglioside GD1b or GT1b, all of which contain an α(2,3)-linked sialic 
acid residue [2-3] and is caveolae-mediated endocytosed and traffics to the nucleus via 
the endoplasmic reticulum [4].  Viral uncoating is believed to occur within tubulo-
reticular structures at the nuclear periphery prior to nuclear entry [4-5]. Once in the cell 
nucleus, the uncoated chromosome is transcribed. Early gene transcription products result 
in T antigens that cause quiescent cells to re-enter the cell cycle and increase cellular 
growth and proliferation. In permissive host cells the T antigens, acting as regulatory 
proteins, direct the remaining events, resulting in a productive infection. The completion 
of the process consists of viral DNA replication and transcription of late genes for the 
production of the structural proteins (VP1, VP2 and VP3) that constitute the capsid [1, 4, 
6-8]. Viral capsomeres assemble around the daughter chromosomes in the nucleus, to 
form stable viral particles. Viral egress is thought to occur via cell lysis, although virions 
have been detected within vesicles in the cytoplasm [5]. 
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BKV infection typically occurs during childhood, without specific symptoms, 
followed by a state of non-replicative infection in various tissues, with the urogenital tract 
as the principal site [9]. In the setting of relative or absolute cell-mediated 
immunosuppression, dramatic increase in BK viral replication occurs, resulting in the 
lytic destruction of infected uroepithelial cells, which in turn induces the influx of 
inflammatory immune cells [10]. This destruction of kidney cells most often occur in 5–
8% of kidney transplants resulting in organ loss in half of these cases and is termed BKV- 
associated nephropathy (BKVN) [4, 7, 11].  Rise in the incidence of Polyomavirus viruria 
and viremia have been detected in recipients of bone marrow, kidney and heart 
transplants, as well as an increase in viruria in HIV-infected individuals [12]. The 
potential for BK replication at distant sites such as the salivary gland may certainly exist 
in the setting of HIV infection [12-13].           
While it is clear that BKV infection is a ubiquitous childhood infection, BKV 
transmission is not currently well understood.  The present studies were undertaken to 
determine whether BKV could infect and replicate within salivary gland cells resulting in 
virus production and potentially transmission.   We have detected BKV in the saliva of 
patients with HIV-associated salivary gland pathology and in healthy individuals. In 
order to begin to decipher BKV pathogenesis within the salivary gland cell it was 
essential to develop an in-vitro model system.  We have chosen to characterize BKV 
infection in submandibular (HSG) and parotid (HSY) gland cell lines. These cells were 
able to support viral entry, transcription, translation and virion production and BKV 
infection could be inhibited by saturating the capsid protein with its ganglioside receptor.  
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MATERIAL AND METHODS 
Patients and Sample Collection 
HIV positive patients from UNC hospitals dental clinic/infectious disease clinic and 
healthy volunteers were recruited to participate in the IRB approved study (04-DENT-
356). Five milliliter saliva samples from HIV positive and negative individuals were 
collected, contents centrifuged and pelleted and DNA extracted by Qiagen DNeasy kit 
according to manufacturers’ instruction.   
 
Cell culture and virus  
HSY cells are a neoplastic epithelial cell line initially established in culture from a 
human parotid gland adenocarcinoma[14]. HSG cells are an epithelial cell line isolated 
by using tissue culture techniques from an irradiated human submandibular salivary 
gland which showed no neoplastic lesion [15]. HSG and HSY cells were obtained as a 
gift from Dr. B. Baum (NIH) and cultured in McCoy’s 5A medium (Sigma) and 
Dulbecco’s minimal essential medium (DMEM; Sigma), respectively.   African monkey 
kidney cells or Vero cells (American Type Culture Collection [ATCC]) were also 
cultured in DMEM (Sigma). All cell types were grown in medium supplemented with 
10% fetal bovine serum (FBS) (Sigma), and 1% penicillin-streptomycin 
(pen/strep)(Gibco) unless otherwise stated and maintained in a humidified 370C, 5%CO2 
chamber. BKV stocks were initially propagated in Vero cells from virus obtained from 
ATCC (VR-837). Viral lysates were made through three cycles of freezing the infected 
cells and supernatant at -800C and thawing at 370C.  
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Hemagglutination assay 
 BK virus was titered using hemagglutination assay as previously described [16]. 
Briefly, 90 ul of culture fluid was added to 10 ul of 2.5% NP-40 in PBS and incubated at 
370C for 30 min. Two-fold dilutions of the treated-fluid in 25 ul volume of HA buffer 
was transferred into V-bottomed 96-well microtiter plates and 25 ul of a cold 0.5% 
suspension of guinea pig erythrocytes was added to each well. Plates were then incubated 
at 40C for nonagglutinated cells to settle (about 2h). BK viral titer was taken to be the 
highest dilution in which >75% of the erythrocytes are agglutinated.  
  
Conditions of infection 
HSY, HSG and Vero cell monolayers were trypsinized, washed and resuspended 
in fresh culture medium supplemented with 2% FBS and 1% pen/strep and plated in poly-
L Lysine coated 8-well chamber slides (Falcon), 12 well dishes or 35-mm diameter well 
culture plates at a concentration of 6.5 x 105 cells/ml. 64 HAUs of BKV was then added 
to the dish and allowed to infect for 24h. At 24h post infection (hpi), virus was removed 
from the culture medium, cells were washed with 1X PBS and replaced with fresh 
medium. The infection of HSG and Vero cells was blocked by pre-incubation of BKV 
with 60ug/ml or 100ug/ml purified mixed gangliosides (Matreya, LLC) in media for 2-6 
hrs at 370C. At various times post infection the cell monolayers or supernatant were 
further processed for IFA, protein, RNA or DNA isolation, as described below.  
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Indirect immunofluorescence (IFA) 
At stated times post-infection, cells were fixed for 10 min with 50% 
methanol/50% acetone, dried at RT then incubated at -200C overnight for antigen 
retrieval. Fixed cells were then thawed at RT, rehydrated with 1XPBS/TritonX and 
incubated with PAb416 (Genetex) antibody (1:30) specific for SV40 T antigen. PAb416 
has been shown to cross react with BKV T antigen and is commonly used for BKV T Ag 
detection. NCL-JCBK (Novocastra) antibody (1:20) was used to detect BKV VP1 
protein. NCL-JCBK is specific for both BK and JC VP1 protein detection. Both 
antibodies were incubated with fixed cells for 1 hr at 370C followed by a fluorescencein-
conjugated anti-mouse (Sigma) antibody (1:20). DAPI (Invitrogen) (1:10,000) was used 
to stain the nucleus and brefeldin A, BODIPY 558/568 conjugate to stain the 
endoplasmic reticulum (Invitrogen). At least ten random fields of positively stained cells 
were counted to determine percent infection. Nikon FXA with Q camera or Olympus 
IMT2 fluorescent microscopes were used to take photographs of cells.   
  
Immunoblotting  
Total cell protein was extracted using 1% SDS lysis buffer (1% (w/v) SDS, 
0.05M Tris.Cl pH8, 1mM DTT). Protein concentrations were determined using the 
BioRad protein assay, and equal amounts of protein were electrophoresed on a 10% Bis-
Tris polyacrylamide minigel (Invitrogen). PAb416 (1:200) (Genetex) in 5% non-fat dry 
milk in 0.1% Tween-20 PBS (PBS-T) was used to detect T Ag expression and Actin (C-
11)-R sc-1615-R (1:1000)(Santa Cruz Biotechnology) in 1% BSA/TBS-T for actin 
expression. After washing in PBS/TBS-T, blots were probed with a horseradish 
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peroxidase-conjugated secondary antibody (1:10,000) (Promega). Antibody complexes 
were detected using SuperSignal West Pico Chemiluminescent substrate (Thermo 
scientific) and exposed to film (Kodak). 
 
RNA isolation and real-time RT-PCR amplification  
 Total RNA was extracted using TRizol (Invitrogen) as described by the 
manufacturer. Contaminating DNAs were removed by use of RQ1 DNase kit (Promega) 
as described by the manufacturer. cDNA was generated using 20µg RNA, random 
primers and the SuperScriptTM II Reverse Transcriptase (RT) Kit (Invitrogen) as 
described by the manufacturer. A non-RT enzyme reaction was performed for each 
sample as a negative control for cDNA synthesis. cDNA was then subjected to real-time 
PCR analysis using Roche LightCycler 480 Syber Green I Master Mix as a detector in the 
Roche Light Cycler 480.  Previously published primers for T Ag [17] and VP1 [18] were 
used. Gene expression values were normalized to the levels of β-actin transcripts, using 
the 2– C(T) method, and are presented as the changes (n-fold) in T Ag and VP1 
transcript levels, with the levels in uninfected/mock samples arbitrarily set to 1. 
 
Encapsidated viral genome assay  
The detection of infectious virus being released from HSG cells was performed on 
HSG cell supernatant collected at stated times post infection. Supernatant was passed 
through a 0.45uM filter and DNase-treated or used to infect Vero cells as previously 
described [3]. To degrade free DNA not encapsidated within virions, supernatant was 
treated with 250U DNase (Promega) or water for 15 min at 560C, followed by enzyme 
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inactivation at 650C for 10 min. To release viral DNA (vDNA) from capsids, proteinase 
K was used as described in the blood and body fluid spin protocol of the QIAamp DNA 
blood minikit (QIAGEN). DNA was eluted in 100 µl of sterile water. Levels of viral 
DNA were determined using primers for T Ag in real time PCR as described above. A 
plasmid, pBKV containing the entire genome of BKV, a gift from Volker Nickeleit 
(UNC-CH) was used to derive standard curves for viral DNA quantitation. 
 
Virus purification and labeling and confocal microscopy  
BKV was propagated in Vero cells and purified as previously described[2]. 
Briefly, viral lysates, including all cell debris, were adjusted to pH 7.4 with 0.5 M HEPES 
(pH 8.0) and centrifuged at 8,000 x g for 30 min at 4°C. The supernatant was removed, 
and the pellet was resuspended in 5 ml of buffer A (10 mM HEPES [pH 7.9], 1 mM 
CaCl2, 1 mM MgCl2, and 5 mM KCl). The pH of the lysate was then adjusted to 6.0 with 
0.5 M HEPES (pH 5.4), and 5 units of type V neuraminidase (Sigma) was added and 
incubated for 1 h at 25°C. The solution was returned to pH 7.4 through the addition of 0.5 
M HEPES (pH 8.0) and then heated to 40°C and centrifuged at 16,000 x g for 5 min. The 
supernatant was removed and saved, while the pellet was further incubated with 5 ml of 
buffer A containing 0.1% deoxycholate at 25°C for 15 min and then centrifuged at 16,000 
x g for 5 min. The supernatant was removed, combined with the previous supernatant, 
and centrifuged through a 15% sucrose cushion into 35 g/100 ml CsCl at 141,000 x g in a 
Beckman Optima LE-80K ultracentrifuge using a Beckman tube (28 by 89 mm) in a 
Beckman SW28 rotor for 3.5 h at 20°C. Virus was dialyzed against buffer A, and titers 
were determined using the hemmaglutination assay and DNase protection assay.  
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Purified BKV was then labeled using Alexa Fluor 488 microscale protein labeling 
kit (Molecular Probes) as directed by the manufacturer (bovine serum albumin (BSA) and 
1X PBS were used as positive and negative labeling controls). Briefly, 100µl of purified 
viral solution or 1mg/ml BSA or 100µl 1X PBS was transferred to a reaction tube and 
10µl of 1M sodium bicarbonate added, 33nmol Alexa Fluor tetrafluorophenyl ester was  
added and the reaction mixture was incubated for 15 min. After incubation, 50µl of the 
conjugate reaction mixture was layered on the resin bed in the microcentrifuge tube and 
centrifuged at 16,000xg for 1 min. The eluted virus was then used to infect HSG or Vero 
cells in poly-L lysine coated 8-well chamber slides (Falcon). At 24 and 48 hpi, 
monolayers of cells were fixed with 50% methanol/ 50% acetone for 10 minutes followed 
by addition of TO-PRO3 (Invitrogen) reagent at 1:10,000 for 2 min to stain the cell 
nucleus. Cells were then washed and stored in 1X PBS and used to detect virion entry 
using an Olympus FV 500 microscope. 
 
Electron microscopy 
 HSG cells were infected with BKV or media (mock) and at 5 dpi the cells were 
washed with 1X PBS and the cell monolayers fixed with 3% glutaraldehyde in 0.15 M 
sodium phosphate buffer.  Cells were then post-fixed with potassium ferrocyanide-
reduced osmium tetroxide. Cells were embedded in situ in Polybed 812 epoxy resin and 
cut into ultrathin sections of 70 nm. Sections were post-stained in uranyl acetate and lead 
citrate then photographed using a LEO EM-910 transmission electron microscope (LEO 
Electron Microscopy Inc. Thornwood, NY) with Orius camera at 80 kV. All sections 
were cut parallel to the substrate. 
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RESULTS 
BKV DNA detection in oral fluids.  
Salivary shedding of BKV was assessed in a small cohort of healthy and immune 
suppressed individuals who had HIV disease.  The mean BK copy number in saliva from 
individuals with HIV and an associated salivary gland disease was 3644 (n=11).  HIV 
negative individuals had mean BK copy numbers that were significantly less at 26 (n=7) 
(Figure 1). 
 
BK virions enter human salivary gland cells.  
To determine whether BKV could enter salivary gland cells in-vitro virion 
labeling was employed (Figure 2).  Fig. 2 shows CsCl purified BKV labeled with Alexa 
Fluor™ 488 (green) and the stained nucleus (red). Bovine serum albumin (BSA) and 1X 
PBS (data not shown) were also labeled with Alexa-Fluor™ 488 as positive and negative 
labeling controls, respectively. HSG or Vero cells were incubated with BKV at 64 HAU 
for 24 h, washed and fixed.  Using confocal visualization, at 24 h BKV particles were 
located in the cell cytoplasm of both HSG and Vero cells. At 48 h BKV accumulation 
was detected at the perinuclear region of HSG cells. This type of perinuclear  
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Figure 5.1 BKV DNA detection in oral fluids.  BKV DNA levels in the saliva were 
measured by real time PCR and were found to be significantly higher in patients 
diagnosed with HIV-associated salivary gland disease compared to patients without the 
disease.   BKV levels in persons with HIV-SGD ranged from 101 to 104 copies/ml while 
non-diseased persons ranged from 10-2 to 102 copies/ml. p<0.0001 
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accumulation has previously been described in human kidney cells in vivo  [5] and in 
vitro [19]. We did not observe perinuclear accumulation of virions in Vero cells at the 48 
h time point suggesting that viral uncoating and nuclear entry may have already occurred. 
It has previously been shown in human kidney cells that BKV traffics from the cell 
surface to the nucleus within 12 to 24 h [19] which may explain our inability to detect 
labeled BKV at the stated 48 h time point in Vero cells.  The kinetics of entry and 
uncoating may be cell type specific.  
 
BKVtranscripts expressed in salivary gland cells.  
Upon determination of BKV entry   into salivary gland cells in vitro, the outcome 
of infection was assessed. Viral transcription levels of early gene, T Ag and the late gene, 
VP1 were examined. In both submandibular (HSG) and parotid gland (HSY) cell lines an 
increase in viral transcription of both T Ag and VP1 genes was observed up to 6 dpi 
(Figure 3).  Beyond 6 dpi, cells became over-confluent, lifted off of the plate surface and 
began to die.  A steady increase in transcription of both T Ag and VP1 transcripts was 
detected, generally peaking at 3 dpi. We consistently observed higher levels of VP1 
versus T Ag transcripts in both cell types. This is consistent with the requirement for 
increased amounts of structural protein as compared to non-structural protein for viral 
replication to occur. Small amounts of T Ag are necessary to activate late gene 
transcription. Results were normalized to the levels of β-actin, using the 2– C(T) 
method, and are presented as the changes (n-fold) in T Ag and VP1 transcript levels. 
Uninfected, mock samples were arbitrarily set to 1.  
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Figure 5.2 Detection of BK virions in salivary gland cell lines infected with BKV. A) 
HSG and Vero cells were infected with Alexa-Fluor 488-labeled BK virus (green) or 
Alexa-Fluor 488-labeled BSA (green) or Alexa-Fluor 488-labeled 1X PBS (data not 
shown) as stated in the materials and methods. At stated times post infection, monolayers 
of cells were fixed and observed by confocal microscopy using a 63x lens objective. At 
24 hpi, labeled BKV (green) was detected at the plasma cell membrane of HSG cells and 
within the cytoplasm of Vero cells. At 48 hpi, labeled BKV (green) was detected at the 
perinuclear region of HSG cells and not at all detected in Vero cells.  Labeled BSA 
(green) and 1X PBS (data not shown) was detected only in the extracellular regions of 
both HSG and Vero cells. TO-PRO3 dye was used to stain the cell nuclei (red). White 
arrows point to Alexa-Fluor 488-labeled BK virions.  
Vero BKV-labeled 48 hpi Vero BSA-labeled Vero BKV-labeled 24 hpi
HSG BKV-labeled 48 hpiHSG BKV- labeled 24 hpi HSG BSA-labeled 
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BKVprotein expression in salivary gland cells.  
Translation of T Ag in BKV-infected HSG cells was assessed by immunoblotting 
and immunofluorescence techniques (Figures 4A, 4B and 4C). As expected protein 
expression was delayed compared to mRNA transcription, consistent with previous work 
showing that BK virus replicates slowly in vitro [4, 8, 19]. Nuclear T Ag and VP1 protein 
expression was first detected at 4 dpi by IFA (Figure 4A and B). Based on counting of IF 
positive cells at 5 dpi (data not shown), an average of ten experiments determined the 
percentage of VP1 positive cells was approximately 15%  and the percentage of T ag 
positive cells were 10% or less. Immunoblot consistently detected expression of both 
small and large T antigen at 4 dpi, although in one infection small amounts of protein 
were detected at day 3 (Figure 4C top and middle panel). Collectively, these data indicate 
that BKV gene expression occurred in human salivary gland cells in vitro.  
 
Salivary gland cells release infectious virus into the supernatant.   
In order to determine whether BKV infection of salivary gland cells results in 
productive infection, release of infectious virions from salivary gland cells was assessed. 
BK virions were not detected by electron microscopy in salivary gland cells days 2-4 dpi.  
However,  at 5 dpi 45 -50 nm BK virions were identified within the cell cytoplasm 
similar to those virions detected within BKV infected kidney cells (decoy cells) shed into 
the urine of a kidney transplant patient diagnosed with BKV nephropathy  (Figure 5).  No 
viral particles were detected prior to 5 dpi within the cell cytoplasm. 
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Figure 5.3. BKV replicates in human salivary gland cells. HSG and HSY cells were 
infected with BKV or media alone (mock) as described in the materials and methods. (A) 
At stated times post infection cells were collected, RNA isolated, cDNA generated and 
quantitative real time PCR performed for T Ag and VP1 viral transcripts. Gene 
expression values were normalized to the levels of β-actin transcripts, using the 2– C(T) 
method, and are presented as the changes (n-fold) in T Ag and VP1 transcript levels, with 
the levels in uninfected/mock samples arbitrarily set 1.  
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Figure 5.4 BKV protein expressed in salivary gland cells. At 5 dpi, monolayer of cells 
were fixed and probed for A) T Ag and B) VP1 expression using PAb 416 and NCL-
JCBK antibodies, respectively. Photos are representative BKV-infected (top and middle 
panel) or control mock (bottom panel) HSG cells stained for T Ag (green) and VP1 
(green). DAPI (blue) was used to stain the cell nuclei and Brefeldin A (red) used to stain 
the endoplasmic reticulum. (x20 magnification). C) At stated times post infection cell 
lysates were collected and used for immunoblotting as described in the materials and 
methods. Antibodies against T Ag (top panel) and β-actin (bottom panel) were used. T 
Ag protein was first detected at 4 dpi. 
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Figure 5.5 BK virions detected within salivary gland cells. Representative 
transmission electron micrograph (TEM) of BK virions at x160,000 magnification of 
BKV and mock-infected HSG cells (top panel) at 5 dpi. Bottom panel, BK virions from 
BKV infected kidney cells (decoy cells) in the urine of a BKV-associated nephritis 
patient 
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Time courses were performed during which supernatants from HSG cells were 
collected and filtered at 0, 1, 3, 4 and 5 days post-infection.  Two separate experiments were 
performed in which 1) separate plates were infected and harvested at stated time points 
(data not shown) or  2) a single plate was infected from which supernatant was collected 
over time (Figure 6). Supernatants were then DNAse/Proteinase K treated to detect only 
encapsidated viral DNA (vDNA) or Protienase K-only treated as a control to detect both 
encapsidated and unencapsidated vDNA (data not shown), as previously described [3]. 
Over time post-infection increasing levels of virus was detected by quantitative real-time 
PCR indicating release of encapsidated viral DNA form infected cells.   
The supernatants from HSG cells were also used to infect naive Vero cells. At 5 
days post Vero cell treatment, cells were collected for quantitative real-time PCR, 
immunofluoresence, and immunoblotting. Again, real time results were normalized to the 
levels of β-actin transcripts using the 2– C(T) method, and are presented as the changes 
(n-fold) in T Ag and VP1 transcript levels, with the levels in mock-treated samples 
arbitrarily set to 1. The level of T Ag  and VP1 viral transcripts, were significantly higher 
in Vero cells treated with BKV-infected HSG supernatant over mock-infected HSG 
supernatant (Figure 7A).  Immunofluorescen/ce and immunoblotting techniques detected 
T Ag protein expressed in Vero cells treated with BKV-infected HSG supernatant 
(Figures 7 B and C).  These data suggest that human salivary gland cells can indeed be 
productively infected with BK virus.  
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Figure 5.6.. Encapsidated BK virions released from human salivary gland cells.  
Supernatant of BKV or mock (media only) infected HSG cells were collected at 0, 1, 3, 4 
and 5 dpi, filtered and treated with either proteinase K only to quantify total vDNA (data 
not shown) or DNase followed by proteinase K treatment, to quantify encapsidated 
vDNA only, as described in the materials and methods. Eluted vDNA was then used to 
quantify T Ag copy number using real time PCR analysis. A standard curve (data not 
shown) was constructed using a plasmid coding for BKV T Ag to determine copy 
number.   
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Figure 5.7. Infectious virus released from HSG cells. Supernatant of BKV or media 
only (mock) infected HSG cells were collected at 5 dpi, filtered and used to infect Vero 
cells as described in the materials and methods. At 5 days post treatment with HSG 
supernatant, Vero cells are examined for BKV infection by A) quantitative real time PCR 
analysis B) immunofluorescence and C) immunoblot. A) For real time PCR analysis, 
gene expression values were normalized to the levels of β-actin transcripts, using the 2–
C(T)
 method, and are presented as the changes (n-fold) in T Ag and VP1 transcript 
levels, with the levels in uninfected/mock samples arbitrarily set 1. B) Vero cells were 
fixed at day 5 pi and stained for T Ag (green). DAPI (blue) was used to stain the cell 
nuclei. Representative photograph of BKV T Ag and nuclear staining are shown for 
BKV-infected and control mock Vero cells. C) Immunoblot analysis of Vero cells for 
BKV T Ag (upper panel) and β-actin (lower panel) proteins detected at 5 days post HSG 
supernatant treatment.  
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BKV infects salivary gland cells via gangliosides.  
It has previously been shown that BKV’s receptors include an N-linked 
glycoprotein with α(2,3)-linked sialic acid and gangliosides, GD1b and GT1b  [2-3, 20]. 
As HSG cells were permissive for BKV infection, the use of gangliosides for receptor-
mediated BKV entry into these cells was assessed. A mixture containing all of these 
gangliosides in addition to GM1 and GD3 was utilized as the receptor for BKV on 
salivary gland cells was unknown.   BKV was pre-incubated with GM1, GD1b, GT1b 
and GD3 to bind and saturate the capsid protein, VP1.   Two different concentrations of 
ganglioside: 60ug/ml and 100ug/ml, were pre-incubated with BK virus prior to infection 
of HSG and Vero cells.  Using real-time quantitative PCR, a 28 fold decrease was 
detected in viral transcription of T Ag in HSG cells infected with both BKV/60ug and 
BKV/100ug ganglioside mix compared to cells infected with BKV/DMSO alone.  A 273 
fold and 72 fold decrease was detected in Vero cells infected with BKV/60ug and 
BKV/100ug, respectively (Figure 8A). For VP1 viral transcripts in HSG cells we 
observed a 46 and 81 fold decrease in BKV/60ug and BKV/100ug ganglioside mix, 
respectively, compared to cells infected with BKV/DMSO alone. In Vero cells we 
detected a 402 and 62 fold decrease in VP1 transcripts when infected with BKV/60ug and 
BKV/100ug ganglioside mix, respectively.  
A decrease in the number of T Ag expressing cells was also detected by IFA upon 
infection with the BKV/ganglioside mix versus cells exposed to BKV/DMSO (Figure 
8B). In HSG cells, at 4 dpi, a 75% decrease in T Ag expressing cells was detected with 
the BKV/100ug ganglioside infection and a 45% decrease detected with BKV/60ug 
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ganglioside infection.  While at 6 dpi, we observed 61% and 96% percent decrease in 
BKV/60ug and BKV/100ug infections, respectively. In Vero cells, at 4 and 6 dpi, a100% 
decrease was detected with both the BKV/60ug and BKV/100ug ganglioside infections.  
These data indicate that human salivary gland cells are infected with BKV via receptor 
mediated VP1 entry and suggest that there may be a difference in receptor abundance 
between salivary gland cells and kidney cells.  
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Figure 5.8 Inhibition of BKV infection in salivary gland cell lines via gangliosides.  
HSG and Vero cells were infected with BKV in the absence or presence of a ganglioside 
mix or negative control media only (mock) and analyzed for T Ag expression at stated 
times post infection. A) Real time RT-PCR analysis of T Ag (top panel) and VP1 (bottom 
panel) transcripts from HSG (white bar) and Vero (checkered bar) cells at 5 dpi. Two 
concentrations of ganglioside mixtures were used, 60ug/ml or 100ug/ml, to incubate with 
BKV prior to infection. Gene expression values were normalized to the levels of β-actin 
transcripts, using the 2– C(T) method, and are presented as the changes (n-fold) in T 
Ag/VP1 transcript levels, with the levels in uninfected/mock samples arbitrarily set to 1. 
Shown is a representative experiment, this study was performed three times in duplicate.  
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B. 
Figure 5.8 (continued). B) Immunofluorescence analysis of T Ag protein expression 
from HSG (top panel) and Vero (bottom panel) cells.  At 4 and 6 dpi monolayer of cells 
were fixed and stained for T Ag (green) and DAPI (blue) used to stain the cell nuclei. The 
number of T Ag positive cells were counted per well and plotted as the percent decrease 
of T Ag positive cells in the presence of ganglioside compared to T Ag positive cells in 
the absence of ganglioside [(100 – (BKV only ÷ BKV/ganglioside x 100)].  Bottom panel 
shows representative photos of IFA staining for T Ag in HSG and Vero cells. (x20 
magnification).  
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DISCUSSION 
The present data demonstrate for the first time, BKV detection in saliva and 
evidence that human salivary gland cells can be productively infected with BK virus.  
This suggests that while kidney/uroepithelial cells have long been known to be a site of 
BKV replication and latency, the salivary gland may also constitute an infectious 
reservoir for BKV.  Although the natural route of BKV transmission has not been 
resolved [1, 9], our studies suggest a potential for oral BKV transmission.  
Previous studies have investigated the presence of BKV DNA by polymerase 
chain reaction (PCR) in saliva from HIV-immunodeficient individuals and healthy 
controls but were not detected in their cohort [21]. Our studies however, using 
quantitative real-time PCR analysis detected BKV DNA in saliva samples from HIV 
positive patients and healthy controls. And like most opportunistic pathogens, BKV DNA 
was detected in the saliva at higher levels in immunocompromised patients compared to 
healthy individuals.  
The detection of labeled BK virions within the cytoplasm of salivary gland cells 
confirmed BKV entry. In salivary gland cells, labeled virus was still detected at 48 hpi 
while labeled virus was no longer detected in Vero cells at the same time point perhaps 
due to viral uncoating and entry into the nucleus. Viral gene products were first observed 
at 24 hpi for both T Ag and VP1 using real time RT-PCR, with viral transcription 
peaking at about 3 dpi for both submandibular and parotid gland cell infection. Protein 
expression was first detected at 4 dpi by immunoblot and IFA. While BKV transcripts 
were detected in abundance the expression of viral encoded proteins were more modest. 
The difference in mRNA versus protein levels may reflect the decreased stability of the 
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BKV T Ag protein.  Productive infection was further substantiated by the detection of 
virions by EM at 5 days post infection, as well as the presence of DNAse resistant virus 
in the supernatant. These virions increased over time and were used to infect naïve Vero 
cells. Interestingly, the kinetics of infection appeared to be slower in salivary gland cells 
than in kidney cells.   
BKV entry into salivary gland cells was inhibited by blocking VP1 via 
ganglioside saturation, as has previously been shown in Vero cells [22]. As expected viral 
transcription was more significantly diminished in the presence of 100 ug/ml ganglioside 
compared to 60 ug/ml in the salivary gland cells. Similar trends were observed in the 
Vero cell line upon ganglioside treatment. Likewise a consistent decrease in viral protein 
expression was detected with ganglioside treatment in both salivary gland and Vero cells. 
The high incidence of BKV infection in the world population raises obvious 
questions about the mode of transmission from one individual to another. Given the 
known latency of the virus in the kidney, urine would appear to be a natural vehicle for 
spread within and between families. However, a variety of laboratory techniques have 
been used to assess the prevalence of viruria in the pediatric age groups, resulting in very 
low yield varying from 4% to 26.7%  [23]. Transplancental transmission of BKV from 
mother to fetus has also been evaluated [24-27]. The data thus far however is 
controversial, with one group demonstrating 50% of their infants expressing BKV 
specific IgM antibodies in infants whose mothers seroconverted during pregnancy [25-
26]. While others have shown consistently negative results for BKV-specific IgM in 
neonatal and cord blood samples drawn from the offspring of mothers excreting viral 
inclusion bearing cells in the urine [24]. Transplancental transmission of polyomavirus 
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has been demonstrated in mice [28], and it is conceivable that the same could occur in 
man. BKV DNA has also been detected in feces, blood, semen, genital tissues, peripheral 
blood mononuclear cells (PBMC), and normal skin biopsies, hence it is possible that the 
virus maybe transmitted by intimate contact with infected individuals [29-31]. 
 The possibility of feco-oral transmission has recently been raised upon the 
detection of BKV DNA in urban sewage [29]. This possibility may also be considered as 
potentially complementary to our studies because swallowed material passes the mouth 
and nasopharynx and viruses transmitted through the oral-fecal route may be able to 
multiply in the throat, for example, in the salivary glands or tonsils. Additionally, both 
BKV and SV40 have been detected in the tonsils of immunocompetent children [32] and 
BKV detected in the nasopharyngeal aspirates of children with acute respiratory tract 
disease [21, 32-33]. Again, consistent with our studies indicating that BKV is present in 
the oral cavity and is possibly a mode of transmission from human to human. The 
presence of BKV in the saliva and its ability to replicate in salivary glands cells in vitro 
further suggests a role for oral transmission since BKV was detected in the saliva of both 
healthy and diseased patients in our study.  
In conclusion, we have detected BKV in oral fluids and have shown that BKV is 
capable of permissive infection of salivary gland cells in vitro.  To our knowledge these 
studies provide the first analysis of BKV salivary gland infection and replication.  To the 
extent that parotid (HSY) and submandibular gland (HSG) cells can sustain low levels of 
BKV replication, substantiates BKV’s presence in oral fluids originating within these 
glandular cells and confirms the potential for BKV oral transmission.  These data may 
provide a foundation critical for further understanding BKV infection and pathogenesis. 
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The experiments described in this paper define a system in which BKV lytic replication 
can be studied in-vitro using a physiologically relevant cell type.  The characterization of 
BKV infection of these cells set the groundwork for future studies to better understand 
how BKV is able to persist within the human host and reactivate under immuno-
suppressed conditions. Further studies will help us to identify factors that influence the 
vulnerability of salivary gland epithelial cells to BKV infection and more fully define 
BKV’s role in disease. Determination of the cellular pathways that are altered may allow 
us to target and implement appropriate interventions that would decrease the morbidity 
associated with BKV-associated salivary gland pathologies.  
 
 
 
 
. 
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CHAPTER 6 
 
GENERAL CONCLUSION 
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Salivary gland diseases (SGD) are characterized as enlargement of the parotid 
gland and development of lymphoepithelial cysts and lymphoma and/or a complaint of 
xerostomia causing pain, dental caries, oral candidiasis, difficulty eating and facial 
disfigurement. The goal of this dissertation was to investigate the role for an etiologic 
agent in salivary gland diseases, specifically HIV-associated salivary gland disease and 
Sjogren’s Syndrome. HIV-SGD has been universally established as among the most 
important AIDS-associated oral lesions. In developing countries the incidence of HIV-
SGD has been reported to be as high as 48% of HIV-1 pediatric patients and is increasing 
in the adult population worldwide [1-2]. SS on the other hand, is the second most 
common autoimmune disorder, affecting approximately four million Americans, with the 
disease affecting women 9 times more frequently than men.  Histologically, HIV-SGD 
and SS are very similar except that in HIV-SGD, there is a lymphocytic infiltration of 
CD8 T cells compared to CD4 T cells in SS. Despite the fact that HIV-SGD and SS were 
both initially described twenty and two hundred years ago, respectively, the etiologic 
agent responsible for these diseases are currently unknown.  
Epidemiologic data showing different rates of HIV-SGD in children (20-47%) 
versus adults (3-7.8%) suggest an opportunist as an etiologic agent [3]. Further, the 
incidence of salivary gland disease among HIV infected patients increased significantly 
following the introduction of HAART, reminiscent of opportunistic infections triggered 
by immune reconstitution [2].   Based on epidemiologic correlates and the link to 
lymphoma development, [4] we postulated that HIV-SGD was a manifestation of DNA 
tumor virus infection.   
 153
Opportunistic DNA tumor viruses include herpesvirus, papillomavirus and 
polyomavirus families. Herpesvirus and polyomavirus have been associated with 
significant human disease in immune compromised individuals eg. KSHV in HIV/AIDS 
and JCV in kidney transplant patients. Papillomavirus have been associated with cervical 
cancer and warts. Additionally, mice infected with polyoma virus develop enlarged 
parotid glands and a percentage of the mice develop malignancy.  
While herpes and papilloma viral gene products were not detected in HIV-SGD, 
polyomavirus nucleic acids and antigens were consistently detected (Chapter 2). 
Polyomaviruses, SV40 and JCV DNA were not detected, however BKV-specific primers 
consistently detected BKV in HIV-SGD. BKV belongs to the polyomavirus family, along 
with SV40 and JC virus and is ubiquitous in the human population [5]. The viral capsid is 
icosahedral and has a diameter of 45-50 nm. The genome consists of a closed circular 
double-stranded DNA molecule with approximately 5 kb. BKV genome consists of an 
early region, a late region and a regulatory region (RR) containing promoters, enhancers 
and the replication origin. The genome is transcribed bi-directionally from the origin, 
with the early region encoding for two non-structural proteins: large tumor antigen 
(LTag), and small tumor antigen (STag). The late region encodes for structural capsid 
proteins VP1, VP2 and VP3 and the non-structural agnoprotien [5].  
BKV infection typically occurs during childhood, without specific symptoms, 
followed by a state of non-replicative infection in various tissues, with the urogenital tract 
as the principal site [6]. In the setting of relative or absolute cell-mediated 
immunosuppression, dramatic increase in BK viral replication occurs, resulting in the 
lytic destruction of infected uroepithelial cells, which in turn induces the influx of 
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inflammatory immune cells [7]. This destruction of kidney cells most often occur in 5–
8% of kidney transplants resulting in organ loss in half of these cases and is termed BKV- 
associated nephropathy (BKVN) [8-10]. Typically in BKVN there is a rise in the 
incidence of Polyomavirus shedding in the urine and blood.  
This observation of BKV viruria and viremia in BKVN led to the investigation of 
BKV shedding in the oral cavity and peripheral blood of HIV-SGD patients in whom we 
previously detected BKV within the salivary gland. BKV shedding was detected in oral 
fluids of diseased patients at significantly higher levels compared to healthy subjects. 
Chapter 2 of this dissertation described the first report of a BKV salivary gland tropism, 
BKV shedding in oral fluids and evidence for a firm link between BKV and HIV-SGD. 
The presence of BKV in the saliva and its ability to replicate in salivary glands cells in 
vivo suggest a role for oral transmission.  
In the case of SS, several viruses have been investigated as playing a role in 
disease, for example, Epstein Barr virus (EBV), Cytomegalovirus (CMV) and 
Coxsackievirus but the evidence is contradictory and requires further study. In chapter 3 
of this dissertation, preliminary studies indicate an association between SS and BKV, 
however more patient samples are needed to increase the statistical significance of 
causation between BKV and salivary gland pathology, including saliva, blood and urine 
samples. This is the first description however of an association between BKV infection 
and SS. 
To understand the consequence of BKV infection in HIV-SGD, differential gene 
expression studies were performed and was described in chapter four of this dissertation. 
Suppressive subtractive hybridization (SSH) technique was used to compare gene 
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expression profiles between HIV-SGD and healthy control biopsies. The results indicated 
that a novel non coding RNA, metastasis associated lung adenocarcinoma transcript 1 
(MALAT-1) was highly up-regulated in the disease. Typically MALAT-1 is widely 
expressed in normal tissue and while little is known about its function, appears to be a 
potentially generic marker for epithelial carcinomas [11-16].  
MALAT-1 up-regulation was consistently detected in BKV T antigen-expressing 
HIV-SGD.  A mouse model of polyomavirus associated salivary gland disease was 
explored to confirm Tag mediated MALAT-1 up-regulation in vivo. Mice infected with 
polyomaviruses not only develop salivary gland disease but often go on to develop 
malignancies within the glands [17-18].  A mouse polyoma middle T antigen-expressing 
transgenic model with SGD pathology was used [17].   Interestingly, MALAT-1 was 
highly expressed in transgenic animals expressing the functional homologue of the BKV 
oncoprotein compared to wild type animals.   Similarly in SS, MALAT-1 was determined 
to be up-regulated in patients in whom BKV was detected. This dissertation describes for 
the first time the association of a DNA tumor virus with increased expression of a tumor-
associated transcript within two similar disorders (HIV-SGD and SS), both of which have 
been shown to be occasionally associated with lymphoma development.   
In vitro studies were also performed to confirm BKV’s role in MALAT-1 up-
regulation. Cell lines expressing BKV gene products also resulted in over-expression of 
the MALAT-1 transcript as shown in chapter 4 of this dissertation. In an initial step 
toward understanding how BKV regulates MALAT-1, a reporter assay was developed to 
assay activation of MALAT-1’s enhancer/promoter region. Upon BKV infection 
increased reporter activity was observed suggesting that BKV can regulate MALAT-1 at 
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the transcription level. This is the first description of a mechanism for MALAT-1 
regulation.  
Closer inspection of the MALAT-1 gene revealed features of a primary miRNA 
(pri-miRNA) at its 3’ end.  miRNAs are single-stranded RNA molecules of 21-23 
nucleotides in length, which regulate gene expression. miRNAs are encoded by genes 
from whose DNA they are transcribed but miRNAs are not translated into protein (i.e. 
they are non-coding RNAs); instead each primary transcript (a pri-miRNA) is processed 
into a short stem-loop structure called a pre-miRNA and finally into a functional miRNA. 
Mature miRNA molecules are partially complementary to one or more messenger RNA 
(mRNA) molecules, and their main function is to down-regulate gene expression. Like 
known miRNAs, MALAT-1 is a non-coding transcript, folds into a short stem loop 
structure at the 3’ end and is conserved across mammalian species. Investigation of 
MALAT-1 as a miRNA is currently being explored and potential targets in SGD will be 
determined.  
All of the work on BKV pathogenesis to date has been performed in kidney cells, 
the known site of viral latency. To truly understand BKV pathogenesis in SGD and to 
confirm host cell gene modulations observed in HIV-SGD and SS, an in vitro model of 
BKV infection of salivary gland cells was created. Each step of BKVs viral life cycle was 
examined, including viral entry, replication, egress and infectivity. Parotid (HSY) and 
submandibular (HSG) salivary gland cell lines were used to create the  in vitro model. 
Using these cells, we were able to observe viral entry, mRNA transcription, protein 
expression and DNA replication over the course of infection. Results indicated that BKV 
was capable of replicating efficiently and producing infectious virus particles within 
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these cells. We also determined that BKV entered these cells via gangliosides, as has 
previously been shown to be a receptor for BK virus on kidney cells. To our knowledge 
these studies provide the first analysis of BKV salivary gland infection and replication.  
To the extent that parotid (HSY) and submandibular gland (HSG) cells can sustain low 
levels of BKV replication, this substantiates BKV’s presence in oral fluids originating 
within these glandular cells and confirms the potential for BKV oral transmission.   
Further evidence confirming that BKV plays a role in HIV-SGD was published by 
Leggott et. Al [19]. Leggott described a pediatric case of HIV-SGD in which the patient 
had been diagnosed for more than 5 years, and had considerable disfiguring enlargement 
that was firm, painless and associated with xerostomia and rampant caries. This patient 
had two labial salivary gland biopsies, and a fine-needle biopsy of the parotid 
demonstrated no evidence of EBV, CMV or HIV in the tissues. The same child, after 5 
years of chronic parotid swelling, started steroid therapy for her HIV-associated kidney 
disease. Within 4 days of starting therapy, her parotid enlargement had completely 
resolved. This suggests perhaps an inflammatory origin for the lesion or possibly a viral 
infection that may have been present both in the kidneys and parotid gland that was 
resolved simultaneously, such as the BK virus which causes kidney disease in immune 
suppressed individuals which we have shown to be present in salivary glands cells of 
HIV-SGD patients (Chapter 2).  
Based on my work and findings in the literature, a model has been proposed to 
describe the pathology of BKV in an individual that develops salivary gland disease 
(Figure 6). BKV is initially acquired via the oral route and can be detected in the saliva 
and salivary glands. Previous work from different groups have detected BKV in the tonsil 
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and peripheral blood lymphocytes and may serve as a reservoir for BKV latency as well 
as a means for dissemination. BK virions can be transported from the salivary gland and 
tonsil through the blood stream via PBMCs to the kidney where it is known to reside and 
remain latent. During immune-suppression, for example in transplant recipients, 
autoimmune disease or in HIV positive individuals, BKV can then become active and 
replicate resulting in kidney disease and/or salivary gland disorders. The factors that 
contribute to BKV-induced disease are largely unknown. However, epidemiological 
studies suggest that the most significant cofactor leading to BKV-induced disease is the 
degree of immunosuppression [20-21]. Reactivated virus can then be detected in the urine 
and saliva and may be important in feco-oral transmission. Viral replication in the 
salivary gland would then lead to up-regulation of the tumor-associated transcript, 
MALAT-1 which has the potential to play a role in malignancy development.  
Based on these studies, it is clear that BKV plays a role in salivary gland disorders 
by infecting and replicating in salivary gland cells. As a result of BKV replication within 
salivary gland cells in immune compromised individuals host cell gene modulations 
occur, as has been shown. Additional studies need to be performed however to further 
investigate the many genes de-regulated in HIV-SGD. Future work include 
characterization of the distinct role of lymphoid/inflammatory infiltrates and of salivary 
epithelial cells in the disease. Using the in vitro model, experiments to confirm 
differential gene expression analysis from HIV-SGD biopsies can be performed. In 
addition, development of an agent-based model that models viral and host protein 
interactions during BKV replication is being created in collaboration with Suzy Vasa and 
Dr. Morgan Giddings based on the in-vitro model.  Collaborations are also currently 
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underway to extend the in vitro model to an ex vivo  model whereby salivary gland cells 
in organotypic cultures, that is salivary gland cells explanted from human tissue that 
differentiate into three-dimensional salivary gland structures similar in function and 
structure to natural human salivary glands, will be infected with BKV and characterized.  
Work from this dissertation will foster studies to better understand how BKV is 
able to persist within the human host and reactivate under immune suppressed conditions.  
Determination of the cellular pathways that are altered may allow us to target and 
implement appropriate interventions that would decrease the morbidity associated with 
HIV-SGD. Currently, Cidofovir is being tested on its effect in BKV-associated kidney 
disease, using our in vitro model we will be able to test the effectiveness of drug therapy 
on BKV replication and infection of salivary gland cells. The fact that both HIV-SGD 
and SS are associated with malignancies ties in the possibility that MALAT-1 up-
regulation observed in these diseases is real and can be the causative agent for these 
lesions. Of course more work would be needed to confirm our preliminary observation 
and the potential for a new miRNA to be described is also very powerful and will be 
further investigated.  
The ability for this work to translate into clinical studies is important seeing that 
translational research is an important factor in today’s society. Drug testing and host and 
cellular gene expression studies can further add to our knowledge of these disease 
processes and allow us to progress our understanding of critical gaps in salivary gland 
disorders. The long range goal of this project is to define the interrelationship of viral 
infection with treatment and prevention strategies.   
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Figure 6. Proposed model of BKV pathogenesis in a patient with salivary gland  
disease . 
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